

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use TECENTRIQ HYBREZA safely and effectively. See full prescribing information for TECENTRIQ HYBREZA.

TECENTRIQ HYBREZA® (atezolizumab and hyaluronidase-tqjs) injection, for subcutaneous use
Initial U.S. Approval: 2024

RECENT MAJOR CHANGES

Indications and Usage (1.2, 1.5)	11/2025
Dosage and Administration, Important Dosage and Administration Information (2.2, 2.3)	11/2025
Warnings and Precautions (5.1)	05/2026
Warnings and Precautions (5.2)	8/2025

INDICATIONS AND USAGE

TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated:

Non-Small Cell Lung Cancer (NSCLC)

- as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on $\geq 1\%$ of tumor cells, as determined by an FDA-approved test. (1.1)
- for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained $\geq 50\%$ of tumor cells [TC $\geq 50\%$] or PD-L1 stained tumor-infiltrating immune cells [IC] covering $\geq 10\%$ of the tumor area [IC $\geq 10\%$]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. (1.1)
- in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. (1.1)
- in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. (1.1)
- for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ HYBREZA. (1.1)

Small Cell Lung Cancer (SCLC)

- in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). (1.2)
- in combination with lurbinectedin, for the maintenance treatment of adult patients with ES-SCLC whose disease has not progressed after first-line induction therapy with TECENTRIQ HYBREZA or intravenous atezolizumab, and carboplatin plus etoposide. (1.2)

Hepatocellular Carcinoma (HCC)

- in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy. (1.3)

Melanoma

- in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma as determined by an FDA-approved test. (1.4)

Alveolar Soft Part Sarcoma (ASPS)

- for the treatment of adult patients and pediatric patients (12 years of age and older who weigh 40 kg or greater) with unresectable or metastatic ASPS. (1.5)

DOSAGE AND ADMINISTRATION

- **TECENTRIQ HYBREZA has different recommended dosage and administration than intravenous atezolizumab products. (2.2)**
- TECENTRIQ HYBREZA is for subcutaneous use in the thigh only. (2.2)
- Do not administer TECENTRIQ HYBREZA intravenously. (2.2)
- **The recommended dosage for adult patients and pediatric patients (12 years and older who weigh 40 kg or greater) is:** TECENTRIQ HYBREZA 15 mL (1,875 mg atezolizumab and 30,000 units hyaluronidase) subcutaneously into the thigh over approximately 7 minutes every 3 weeks. (2.2)

- TECENTRIQ HYBREZA must be administered by a healthcare professional. (2.2)

NSCLC Dosage

- In the **adjuvant setting**, administer TECENTRIQ HYBREZA following resection and up to 4 cycles of platinum-based chemotherapy every 3 weeks for up to 1 year. (2.2)
- In the **metastatic setting**, administer TECENTRIQ HYBREZA every 3 weeks. (2.2)
- When administering with chemotherapy with or without bevacizumab, administer TECENTRIQ HYBREZA prior to chemotherapy and bevacizumab when given on the same day. (2.2)

SCLC Dosage

Administer TECENTRIQ HYBREZA every 3 weeks. Administer TECENTRIQ HYBREZA prior to chemotherapy when given on the same day. (2.2)

HCC Dosage

- Administer TECENTRIQ HYBREZA every 3 weeks.
- Administer TECENTRIQ HYBREZA prior to bevacizumab when given on the same day. Bevacizumab is administered intravenously at 15 mg/kg every 3 weeks. (2.2)

Melanoma Dosage

- Following completion of a 28-day cycle of cobimetinib and vemurafenib, administer TECENTRIQ HYBREZA every 3 weeks with cobimetinib 60 mg orally once daily (21 days on / 7 days off) and vemurafenib 720 mg orally twice daily. (2.2)

ASPS Dosage

- Administer TECENTRIQ HYBREZA every 3 weeks. (2.2)

DOSAGE FORMS AND STRENGTHS

Injection: 1,875 mg atezolizumab and 30,000 units hyaluronidase per 15 mL (125 mg/2,000 units per mL) solution in a single-dose vial. (3)

CONTRAINDICATIONS

TECENTRIQ HYBREZA is contraindicated in patients with known hypersensitivity to hyaluronidase or any of its excipients. (4)

WARNINGS AND PRECAUTIONS

- **Immune-Mediated Adverse Reactions**
 - Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including the following: immune-mediated pneumonitis, immune-mediated colitis, immune-mediated hepatitis, immune-mediated endocrinopathies, immune-mediated dermatologic adverse reactions, immune-mediated nephritis and renal dysfunction, and solid organ transplant rejection. (5.1)
 - Monitor for early identification and management. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment.
 - Withhold or permanently discontinue based on severity and type of reaction.
- **Infusion-Related Reactions:** Pause or slow the rate of injection, or permanently discontinue based on severity of the reaction. (5.2)
- **Complications of Allogeneic HSCT:** Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after being treated with a PD-1/PD-L1 blocking antibody. Follow patients closely for evidence of transplant-related complications and intervene promptly. (5.3)
- **Embryo-Fetal Toxicity:** Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and use of effective contraception. (5.4, 8.1, 8.3)

ADVERSE REACTIONS

- Most common adverse reactions (AR) ($\geq 10\%$) with TECENTRIQ HYBREZA as monotherapy in patients with NSCLC were fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite. (6.1)
- Safety of TECENTRIQ HYBREZA for the approved NSCLC, EC-SCLC, HCC, melanoma and ASPS indications is based on safety of intravenous atezolizumab in these populations. Most common AR with intravenous atezolizumab are presented below by indication and regimen (6.1):
Most common AR ($\geq 20\%$) as monotherapy were:
 - **First-line NSCLC:** fatigue/asthenia.
 - **Metastatic NSCLC:** fatigue/asthenia, cough, decreased appetite, dyspnea, and myalgia/pain.

- ASPS: musculoskeletal pain, fatigue, rash, cough, headache, nausea, hypertension, vomiting, constipation, dyspnea, dizziness, hemorrhage, diarrhea, insomnia, abdominal pain hypothyroidism, pyrexia, anxiety, arrhythmia and decreased appetite.

Most common AR ($\geq 20\%$) in combination with other antineoplastic drugs were:

- NSCLC (with bevacizumab, paclitaxel, and carboplatin): neuropathy fatigue/asthenia, alopecia, myalgia, nausea, diarrhea, constipation, decreased appetite, arthralgia, hypertension, rash, cough.
- Non-squamous NSCLC (with paclitaxel protein-bound and carboplatin): fatigue/asthenia, nausea, diarrhea, myalgia/pain, constipation, neuropathy, alopecia, dyspnea, decreased appetite, cough, vomiting and rash.
- SCLC (with chemotherapy): fatigue/asthenia, nausea, alopecia, decreased appetite, constipation and vomiting.

- HCC (with bevacizumab): hypertension, fatigue and proteinuria.
- Melanoma (with cobimetinib and vemurafenib): rash, musculoskeletal pain, fatigue, hepatotoxicity, pyrexia, nausea, pruritus, edema, stomatitis, hypothyroidism, and photosensitivity reaction.

To report SUSPECTED ADVERSE REACTIONS, contact Genentech at 1-888-835-2555 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

—————**USE IN SPECIFIC POPULATIONS**—————

Lactation: Advise not to breastfeed. (8.2)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 05/2026

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

- 1.1 Non-Small Cell Lung Cancer
- 1.2 Small Cell Lung Cancer
- 1.3 Hepatocellular Carcinoma
- 1.4 Melanoma
- 1.5 Alveolar Soft Part Sarcoma

2 DOSAGE AND ADMINISTRATION

- 2.1 Patient Selection for Treatment of Non-Small Cell Lung Cancer and Melanoma
- 2.2 Important Dosage and Administration Information
- 2.3 Recommended Dosage and Administration Instructions
- 2.4 Dosage Modifications for Adverse Reactions
- 2.5 Preparation Instructions
- 2.6 Storage Instructions

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Severe and Fatal Immune-Mediated Adverse Reactions
- 5.2 Infusion-Related Reactions
- 5.3 Complications of Allogeneic HSCT after PD-1/PD-L1 Inhibitors
- 5.4 Embryo-Fetal Toxicity

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.3 Females and Males of Reproductive Potential
- 8.4 Pediatric Use
- 8.5 Geriatric Use

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics
- 12.6 Immunogenicity

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES

- 14.1 Non-Small Cell Lung Cancer
- 14.2 Small Cell Lung Cancer
- 14.3 Hepatocellular Carcinoma
- 14.4 Melanoma
- 14.5 Alveolar Soft Part Sarcoma
- 14.6 Patient Experience

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Non-Small Cell Lung Cancer

- TECENTRIQ HYBREZA, as monotherapy, is indicated as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with stage II to IIIA [see *Clinical Studies (14.1)*] non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on $\geq 1\%$ of tumor cells, as determined by an FDA-approved test [see *Dosage and Administration (2.1)*].
- TECENTRIQ HYBREZA, as monotherapy, is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained $\geq 50\%$ of tumor cells [TC $\geq 50\%$] or PD-L1 stained tumor-infiltrating immune cells [IC] covering $\geq 10\%$ of the tumor area [IC $\geq 10\%$]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations [see *Dosage and Administration (2.1)*].
- TECENTRIQ HYBREZA, in combination with bevacizumab, paclitaxel, and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.
- TECENTRIQ HYBREZA, in combination with paclitaxel protein-bound and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.
- TECENTRIQ HYBREZA, as monotherapy, is indicated for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ HYBREZA.

1.2 Small Cell Lung Cancer

- TECENTRIQ HYBREZA, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).
- TECENTRIQ HYBREZA, in combination with lurbinectedin, is indicated for the maintenance treatment of adult patients with ES-SCLC whose disease has not progressed after first-line induction therapy with TECENTRIQ HYBREZA or intravenous atezolizumab, carboplatin and etoposide.

1.3 Hepatocellular Carcinoma

TECENTRIQ HYBREZA, in combination with bevacizumab, is indicated for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

1.4 Melanoma

TECENTRIQ HYBREZA, in combination with cobimetinib and vemurafenib, is indicated for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma as determined by an FDA-approved test [see *Dosage and Administration (2.1)*].

1.5 Alveolar Soft Part Sarcoma

TECENTRIQ HYBREZA, as monotherapy, is indicated for the treatment of adult patients and pediatric patients (12 years of age and older who weigh 40 kg or greater) with unresectable or metastatic alveolar soft part sarcoma (ASPS).

2 DOSAGE AND ADMINISTRATION

2.1 Patient Selection for Treatment of Non-Small Cell Lung Cancer and Melanoma

Select adult patients with:

- Stage II to IIIA NSCLC for adjuvant treatment with TECENTRIQ HYBREZA as a monotherapy (following tumor resection and platinum-based chemotherapy) based on PD-L1 expression on tumor cells [see *Clinical Studies (14.1)*].
- Metastatic NSCLC for first-line treatment with TECENTRIQ HYBREZA as monotherapy based on the PD-L1 expression on tumor cells or on tumor-infiltrating immune cells [see *Clinical Studies (14.1)*].
- Unresectable or metastatic melanoma for treatment with TECENTRIQ HYBREZA in combination with cobimetinib and vemurafenib after confirming the presence of a BRAF V600 mutation [see *Clinical Studies (14.4)*].

Information on FDA-approved tests for the determination of PD-L1 expression in metastatic NSCLC or for detection of BRAF V600 mutations in melanoma is available at:

<http://www.fda.gov/CompanionDiagnostics>.

2.2 Important Dosage and Administration Information

- TECENTRIQ HYBREZA has different recommended dosage and administration than intravenous atezolizumab products.
 - To reduce the risk of medication errors, prior to administration, check the vial labels to ensure that the drug being prepared is subcutaneously administered TECENTRIQ HYBREZA and not intravenously administered atezolizumab.
 - Do not substitute TECENTRIQ HYBREZA for or with intravenous atezolizumab products because they have different recommended dosages.
 - Adult patients who are treated with intravenous atezolizumab can switch to subcutaneous TECENTRIQ HYBREZA at their next scheduled dose. Adult patients who are treated with TECENTRIQ HYBREZA can switch to intravenous atezolizumab at their next scheduled dose.
 - Pediatric patients 12 years of age and older who weigh 40 kg or greater and are treated with intravenous atezolizumab can switch to subcutaneous TECENTRIQ HYBREZA at their next scheduled dose [see *Indications and Usage (1.5)*]. Pediatric patients who are treated with TECENTRIQ HYBREZA can switch to intravenous atezolizumab at their next scheduled dose.
- TECENTRIQ HYBREZA is for subcutaneous use in the thigh only. Administer over approximately 7 minutes. Inject in healthy skin and never into areas where the skin is red, bruised, tender, or hard.
- When possible, alternate injections between the left and right thigh. Ensure the injection site is at least 2.5 cm from the previous site.
- Do not administer TECENTRIQ HYBREZA intravenously.
- TECENTRIQ HYBREZA must be administered by a healthcare professional.

- Do **not** administer the remaining volume in the tubing to the patient.
- If using concomitant subcutaneous drugs, administer at sites other than the thighs.

2.3 Recommended Dosage and Administration Instructions

The recommended dosage of TECENTRIQ HYBREZA in adult patients and pediatric patients (12 years of age and older who weigh 40 kg or greater) is one 15 mL injection (containing 1,875 mg of atezolizumab and 30,000 units of hyaluronidase, referred to as TECENTRIQ HYBREZA) administered subcutaneously in the thigh over approximately 7 minutes every 3 weeks.

The recommended dosage for pediatric patients 12 years of age and older who weigh less than 40 kg has not been established [see *Use in Specific Populations (8.4), Clinical Pharmacology (12.3)*].

Administration instructions for TECENTRIQ HYBREZA as monotherapy and in combination with other therapeutic agents are presented in Table 1. For the recommended dosage of each therapeutic agent administered in combination with TECENTRIQ HYBREZA refer to the product's respective Prescribing Information.

Table 1: TECENTRIQ HYBREZA Administration Instructions and Duration of Therapy

Indication	Administration Instructions for TECENTRIQ HYBREZA	Duration of Therapy
Adjuvant Treatment of Non-Small Cell Lung Cancer	Administer TECENTRIQ HYBREZA as monotherapy	Up to one year, unless there is disease recurrence or unacceptable toxicity
Metastatic Non-Small Cell Lung Cancer		Until disease progression or unacceptable toxicity
Non-Small Cell Lung Cancer	Administer TECENTRIQ HYBREZA prior to chemotherapy and bevacizumab when given on the same day.	Until disease progression or unacceptable toxicity
Small Cell Lung Cancer	Administer TECENTRIQ HYBREZA prior to chemotherapy when given on the same day.	
Hepatocellular Carcinoma	Administer TECENTRIQ HYBREZA prior to bevacizumab when given on the same day. Bevacizumab is administered intravenously at 15 mg/kg every 3 weeks.	
Melanoma	Prior to initiating TECENTRIQ HYBREZA, patients should receive the following 28-day treatment cycle of cobimetinib and vemurafenib: <ul style="list-style-type: none"> • Days 1 to 21: cobimetinib 60 mg orally once daily in combination with 960 mg of oral vemurafenib twice daily • Days 22 to 28: withhold cobimetinib and administer vemurafenib 720 mg orally twice daily 	
Alveolar Soft Part Sarcoma	Administer TECENTRIQ HYBREZA as monotherapy	Until disease progression or unacceptable toxicity

2.4 Dosage Modifications for Adverse Reactions

No dose reduction for TECENTRIQ HYBREZA is recommended. In general, withhold TECENTRIQ HYBREZA for severe (Grade 3) immune-mediated adverse reactions. Permanently discontinue TECENTRIQ HYBREZA for life-threatening (Grade 4) immune-mediated adverse reactions, recurrent severe (Grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, or an inability to reduce the daily corticosteroid dosage to 10 mg or less of prednisone or equivalent corticosteroid dosage within 12 weeks of initiating corticosteroids.

Dosage modifications for TECENTRIQ HYBREZA for adverse reactions that require management different from these general guidelines are summarized in Table 2.

Table 2: Recommended Dosage Modifications for Adverse Reactions

Adverse Reaction	Severity ^a	Dosage Modification
Immune-Mediated Adverse Reactions [see Warnings and Precautions (5.1)]		
Pneumonitis	Grade 2	Withhold ^b
	Grades 3 or 4	Permanently discontinue
Colitis	Grades 2 or 3	Withhold ^b
	Grade 4	Permanently discontinue
Hepatitis with no tumor involvement of the liver	AST or ALT increases to more than 3 and up to 8 times ULN or Total bilirubin increases to more than 1.5 and up to 3 times ULN	Withhold ^b
	AST or ALT increases to more than 8 times ULN or Total bilirubin increases to more than 3 times ULN	Permanently discontinue
Hepatitis with tumor involvement of the liver ^c	Baseline AST or ALT is more than 1 and up to 3 times ULN and increases to more than 5 and up to 10 times ULN or Baseline AST or ALT is more than 3 and up to 5 times ULN and increases to more than 8 and up to 10 times ULN	Withhold ^b
	AST or ALT increases to more than 10 times ULN or Total bilirubin increases to more than 3 times ULN	Permanently discontinue
Endocrinopathies	Grades 3 or 4	Withhold until clinically stable or permanently discontinue depending on severity
Nephritis with Renal Dysfunction	Grades 2 or 3 increased blood creatinine	Withhold ^b
	Grade 4 increased blood creatinine	Permanently discontinue
Exfoliative Dermatologic Conditions	Suspected SJS, TEN, or DRESS	Withhold
	Confirmed SJS, TEN, or DRESS	Permanently discontinue

Myocarditis or pericarditis	Grades 2, 3, or 4	Permanently discontinue
Neurological Toxicities	Grade 2	Withhold ^b
	Grades 3 or 4	Permanently discontinue
Other Adverse Reactions		
Infusion-Related Reactions [<i>see Warnings and Precautions (5.2)</i>]	Grades 1 or 2	Pause or slow the rate of injection Premedication with antipyretic and antihistamines may be considered for subsequent doses.
	Grades 3 or 4	Permanently discontinue

^a Based on Common Terminology Criteria for Adverse Events (CTCAE), version 5

^b Resume in patients with complete or partial resolution (Grade 0 to 1) after corticosteroid taper. Permanently discontinue if no complete or partial resolution within 12 weeks of initiating steroids or inability to reduce prednisone to 10 mg per day or less (or equivalent) within 12 weeks of initiating steroids

^c If AST and ALT are less than or equal to ULN at baseline, withhold or permanently discontinue TECENTRIQ HYBREZA based on recommendations for hepatitis with no liver involvement

ALT = alanine aminotransferase, AST = aspartate aminotransferase, ULN = upper limit normal, DRESS = Drug Rash with Eosinophilia and Systemic Symptoms, SJS = Stevens Johnson syndrome, TEN = toxic epidermal necrolysis

2.5 Preparation Instructions

TECENTRIQ HYBREZA does not contain any antimicrobial preservative. If the TECENTRIQ HYBREZA dose is not administered immediately, refer to “Storage Instructions” [*see Dosage and Administration (2.6)*].

- Remove the vial from the refrigerator and allow the solution to acclimate to room temperature. Visually inspect for particulate matter and discoloration prior to administration. Discard the vial if the solution is cloudy, discolored, or visible particles are observed.
- Do not shake, freeze, or dilute.
- The unpunctured vial may be stored at room temperature in ambient light for a maximum of 4 hours prior to the preparation for administration.
- Use an 18-gauge transfer needle and syringe to withdraw the entire contents of the TECENTRIQ HYBREZA solution from the vial. Discard the vial and any residual drug remaining.
- TECENTRIQ HYBREZA is compatible with stainless steel transfer and injection needles, and polypropylene, polycarbonate, polyvinyl chloride, and polyurethane syringe material and subcutaneous administration sets.
- Remove the transfer needle from the syringe and replace it with a subcutaneous administration set (e.g. winged/butterfly) containing 23-gauge, 24-gauge, or 25-gauge hypodermic needle and with a priming volume that does **not** exceed 0.5 mL for administration.
- Prime the subcutaneous administration line with TECENTRIQ HYBREZA to eliminate the air in the line and stop when the fluid reaches the needle.
- Ensure the syringe contains exactly 15 mL of TECENTRIQ HYBREZA after priming the administration line by expelling any excess volume from the syringe.

- Administer immediately to avoid needle clogging.
- Discard any unused portion remaining.

2.6 Storage Instructions

- Do **not** store the prepared syringe that has been attached to the already-primed subcutaneous administration set.
- If the prepared syringe containing TECENTRIQ HYBREZA is not for immediate use, do **not** attach a subcutaneous administration set. The capped syringe may be stored at room temperature [at up to 25°C (77°F)] in ambient room lighting for up to 8 hours and in the refrigerator [2°C to 8°C (36°F to 46°F)] for up to 72 hours. Do **not** shake or freeze.
- If the prepared syringe is stored at 2°C to 8°C (36°F to 46°F), allow the syringe to acclimate to room temperature prior to administration.

3 DOSAGE FORMS AND STRENGTHS

Injection: 1,875 mg atezolizumab and 30,000 units hyaluronidase per 15 mL (125 mg and 2,000 units per mL) clear to slightly opalescent, and colorless to slightly yellow solution in a single-dose vial.

4 CONTRAINDICATIONS

TECENTRIQ HYBREZA is contraindicated in patients with known hypersensitivity to hyaluronidase or to any of its excipients.

5 WARNINGS AND PRECAUTIONS

5.1 Severe and Fatal Immune-Mediated Adverse Reactions

TECENTRIQ HYBREZA is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway, thereby removing inhibition of the immune response, potentially breaking peripheral tolerance and inducing immune-mediated adverse reactions. Important immune-mediated adverse reactions listed under Warnings and Precautions may not include all possible severe and fatal immune-mediated reactions.

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue. Immune-mediated adverse reactions can occur at any time after starting a PD-1/PD-L1 blocking antibody. While immune-mediated adverse reactions usually manifest during treatment with PD-1/PD-L1 blocking antibodies, immune-mediated adverse reactions can also manifest after discontinuation of PD-1/PD-L1 blocking antibodies.

Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of PD-1/PD-L1 blocking antibodies. Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment. In cases of suspected immune-mediated adverse reactions, initiate appropriate workup to exclude alternative etiologies, including infection. Institute medical management promptly, including specialty consultation as appropriate.

Withhold or permanently discontinue TECENTRIQ HYBREZA depending on severity [*see Dosage and Administration (2.4)*]. In general, if TECENTRIQ HYBREZA requires interruption or discontinuation, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone or equivalent) until improvement to Grade 1 or less. Upon improvement to Grade 1 or less, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other

systemic immunosuppressants in patients whose immune-mediated adverse reactions are not controlled with corticosteroid therapy.

Toxicity management guidelines for adverse reactions that do not necessarily require systemic steroids (e.g., endocrinopathies and dermatologic reactions) are discussed below.

Immune-Mediated Pneumonitis

TECENTRIQ HYBREZA can cause immune-mediated pneumonitis, including fatal adverse reactions. The incidence of pneumonitis is higher in patients who have received prior thoracic radiation.

Immune-mediated pneumonitis occurred in 2% (5/247) of patients with locally advanced or metastatic NSCLC receiving TECENTRIQ HYBREZA as monotherapy in the IMscin001 trial [*see Adverse Reactions (6.1)*], including Grade 2 (0.8%), and Grade 1 (1.2%) events. Pneumonitis led to the withholding of TECENTRIQ HYBREZA in one patient.

Systemic corticosteroids were required in 40% (2/5) patients with pneumonitis who received TECENTRIQ HYBREZA as monotherapy. Pneumonitis resolved in both patients. The single patient in whom TECENTRIQ HYBREZA was withheld for pneumonitis reinitiated TECENTRIQ HYBREZA after symptom improvement.

Intravenous Atezolizumab in Combination with Cobimetinib and Vemurafenib:

Immune-mediated pneumonitis occurred in 13% (29/230) of patients receiving intravenous atezolizumab in combination with cobimetinib and vemurafenib in the IMspire150 trial [*see Adverse Reactions (6.1)*], including Grade 3 (1.3%) and Grade 2 (7%) adverse reactions. Pneumonitis led to permanent discontinuation of intravenous atezolizumab in 2.6% of patients and withholding of intravenous atezolizumab in 7.4% of patients.

Systemic corticosteroids were required in 55% (16/29) of patients with pneumonitis. Pneumonitis resolved in 97% of the 29 patients. Of the 17 patients in whom intravenous atezolizumab was withheld for pneumonitis, 10 reinitiated intravenous atezolizumab after symptom improvement; of these, 50% had recurrence of pneumonitis.

Immune-Mediated Colitis

TECENTRIQ HYBREZA can cause immune-mediated colitis, including Grade 3 adverse reactions. Colitis can present with diarrhea, abdominal pain, and lower gastrointestinal bleeding. Cytomegalovirus (CMV) infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis. In cases of corticosteroid-refractory colitis, consider repeating infectious workup to exclude alternative etiologies.

Immune-Mediated Hepatitis

TECENTRIQ HYBREZA can cause immune-mediated hepatitis, including fatal adverse reactions.

Immune-mediated hepatitis occurred in 1.2% (3/247) of patients with locally advanced or metastatic NSCLC receiving TECENTRIQ HYBREZA as monotherapy in the IMscin001 trial [*see Adverse Reactions (6.1)*], including Grade 1 (0.4%) and Grade 3 (0.8%) events. Hepatitis led to the withholding of TECENTRIQ HYBREZA in 0.4% of patients.

Systemic corticosteroids were required in 67% (2/3) of patients with hepatitis who received TECENTRIQ HYBREZA as monotherapy. Hepatitis resolved in 1 of the 3 patients.

Intravenous Atezolizumab in Combination with Cobimetinib and Vemurafenib:

Immune-mediated hepatitis occurred in 6.1% (14/230) of patients receiving intravenous atezolizumab in combination with cobimetinib and vemurafenib in the IMspire150 trial [see *Adverse Reactions (6.1)*], including Grade 4 (1.3%), Grade 3 (1.7%) and Grade 2 (1.3%) adverse reactions. Hepatitis led to permanent discontinuation of intravenous atezolizumab in 2.2% and withholding of intravenous atezolizumab in 1.7% of patients.

Systemic corticosteroids were required in 50% (7/14) of patients with hepatitis. Hepatitis resolved in 93% of the 14 patients. Of the 4 patients in whom intravenous atezolizumab was withheld for hepatitis, 3 reinitiated intravenous atezolizumab after symptom improvement; of these, 33% had recurrence of hepatitis.

Immune-Mediated Endocrinopathies

Adrenal Insufficiency:

TECENTRIQ HYBREZA can cause primary or secondary adrenal insufficiency, including Grade 3 adverse reactions. For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment, including hormone replacement as clinically indicated. Withhold or permanently discontinue TECENTRIQ HYBREZA depending on severity [see *Dosage and Administration (2.4)*].

Immune-mediated adrenal insufficiency occurred in 0.8% (2/247) of patients with locally advanced or metastatic NSCLC receiving TECENTRIQ HYBREZA as monotherapy in the IMscin001 trial [see *Adverse Reactions (6.1)*], including Grade 2 (0.4%) adverse reactions. Adrenal insufficiency led to the withholding of TECENTRIQ HYBREZA in both patients. Systemic corticosteroids were required in 50% (1/2) of patients with adrenal insufficiency who received TECENTRIQ HYBREZA as monotherapy; this single patient remained on systemic corticosteroids.

Hypophysitis:

TECENTRIQ HYBREZA can cause immune-mediated hypophysitis, including Grade 2 adverse reactions. Hypophysitis can present with acute symptoms associated with mass effect such as headache, photophobia, or visual field cuts. Hypophysitis can cause hypopituitarism. Initiate hormone replacement as clinically indicated. Withhold or permanently discontinue TECENTRIQ HYBREZA depending on severity [see *Dosage and Administration (2.4)*].

Immune-mediated hypophysitis occurred in 0.4% (1/247) of patients with locally advanced or metastatic NSCLC in the IMscin001 trial [see *Adverse Reactions (6.1)*] receiving TECENTRIQ HYBREZA as monotherapy, including Grade 1 (0.4%) adverse reactions. Hypophysitis led to the withholding of TECENTRIQ HYBREZA in this patient.

Thyroid Disorders:

TECENTRIQ HYBREZA can cause immune-mediated thyroid disorders. Thyroiditis can present with or without endocrinopathy. Hypothyroidism can follow hyperthyroidism. Initiate hormone replacement for hypothyroidism or medical management for hyperthyroidism as clinically indicated. Withhold or permanently discontinue TECENTRIQ HYBREZA depending on severity [see *Dosage and Administration (2.4)*].

Thyroiditis:

Immune-mediated thyroiditis occurred in 0.8% (2/247) of patients with locally advanced or metastatic NSCLC receiving TECENTRIQ HYBREZA as monotherapy in the IMscin001 trial

[see Adverse Reactions (6.1)], including Grade 2 (0.4%) adverse reactions. Thyroiditis resolved in 50% of patients.

Hyperthyroidism:

Immune-mediated hyperthyroidism occurred in 2% (5/247) of patients with locally advanced or metastatic NSCLC receiving TECENTRIQ HYBREZA as monotherapy in the IMscin001 trial [see Adverse Reactions (6.1)], including Grade 2 (1.2%) adverse reactions. Hyperthyroidism led to withholding of TECENTRIQ HYBREZA in 0.8% of patients.

Anti-thyroid therapy was required in 40% (2/5) of patients with hyperthyroidism who received TECENTRIQ HYBREZA as monotherapy. Of these 2 patients, one remained on anti-thyroid treatment. Of the 2 patients in whom TECENTRIQ HYBREZA was withheld for hyperthyroidism, 1 patient reinitiated TECENTRIQ HYBREZA; this patient did not have recurrence of hyperthyroidism.

Intravenous Atezolizumab in Combination with Cobimetinib and Vemurafenib:

Hyperthyroidism occurred in 19% (43/230) of patients receiving intravenous atezolizumab in combination with cobimetinib and vemurafenib in the IMspire150 trial [see Adverse Reactions (6.1)], including Grade 3 (0.9%) and Grade 2 (7.8%) adverse reactions. Hyperthyroidism led to permanent discontinuation of intravenous atezolizumab in 0.4% and withholding of intravenous atezolizumab in 10% of patients. Antithyroid therapy was required in 53% (23/43) of patients with hyperthyroidism. Of these 23 patients, the majority remained on antithyroid treatment. Of the 24 patients in whom intravenous atezolizumab was withheld for hyperthyroidism, 18 patients reinitiated intravenous atezolizumab; of these, 28% had recurrence of hyperthyroidism.

Hypothyroidism:

TECENTRIQ HYBREZA can cause immune-mediated hypothyroidism, including Grade 4 adverse reactions. Immune-mediated hypothyroidism occurred in 10% (25/247) of patients with locally advanced or metastatic NSCLC who received TECENTRIQ HYBREZA as monotherapy in the IMscin001 trial [see Adverse Reactions (6.1)].

Hormone replacement was required in 68% (17/25) of patients with hypothyroidism who received TECENTRIQ HYBREZA as monotherapy. Two patients with hypothyroidism remained on thyroid hormone replacement.

Intravenous Atezolizumab in Combination with Platinum-based Chemotherapy:

Hypothyroidism occurred in 11% (277/2421) of patients with NSCLC (N = 2223) or SCLC (N = 198) enrolled in five randomized, active-controlled trials, including IMpower150, IMpower130 and IMpower133 receiving intravenous atezolizumab in combination with platinum-based chemotherapy, including Grade 4 (< 0.1%), Grade 3 (0.3%), and Grade 2 (5.7%) adverse reactions. Hypothyroidism led to permanent discontinuation of intravenous atezolizumab in 0.1% and withholding of intravenous atezolizumab in 1.6% of patients.

Hormone replacement therapy was required in 71% (198/277) of patients with hypothyroidism. The majority of patients with hypothyroidism remained on thyroid hormone replacement. Of the 39 patients in whom intravenous atezolizumab was withheld for hypothyroidism, 9 reinitiated intravenous atezolizumab after symptom improvement.

Intravenous Atezolizumab in Combination with Cobimetinib and Vemurafenib:

Hypothyroidism occurred in 26% (60/230) of patients receiving intravenous atezolizumab in combination with cobimetinib and vemurafenib in the IMspire150 trial [see Adverse Reactions (6.1)], including Grade 2 (9.1%) adverse reactions. Hypothyroidism led to withholding of

intravenous atezolizumab in 2.6% of patients. Hormone replacement therapy was required in 52% (31/60) of patients with hypothyroidism. The majority of patients with hypothyroidism remained on thyroid hormone replacement. Of the 6 patients in whom intravenous atezolizumab was withheld for hypothyroidism, 4 reinitiated intravenous atezolizumab after symptom improvement. The majority of patients with hypothyroidism required long term thyroid replacement.

Type 1 Diabetes Mellitus, which can present with Diabetic Ketoacidosis:

TECENTRIQ HYBREZA can cause type 1 diabetes mellitus, including Grade 3 adverse reactions and diabetic ketoacidosis. Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Initiate treatment with insulin as clinically indicated. Withhold or permanently discontinue TECENTRIQ HYBREZA depending on severity [see *Dosage and Administration (2.4)*].

Immune-Mediated Nephritis with Renal Dysfunction

TECENTRIQ HYBREZA can cause immune-mediated nephritis, including Grade 3 adverse reactions.

Intravenous Atezolizumab in Combination with Cobimetinib and Vemurafenib:

Immune-mediated nephritis with renal dysfunction occurred in 1.3% (3/230) of patients receiving intravenous atezolizumab in combination with cobimetinib and vemurafenib in the IMspire150 trial [see *Adverse Reactions (6.1)*], including Grade 2 (1.3%) adverse reactions. Nephritis led to permanent discontinuation of intravenous atezolizumab in 0.4% and withholding of intravenous atezolizumab in 0.9% of patients.

Systemic corticosteroids were required in 67% (2/3) of patients with nephritis. Nephritis resolved in all 3 of these patients. Of the 2 patients in whom intravenous atezolizumab was withheld for nephritis, both reinitiated intravenous atezolizumab after symptom improvement and neither had recurrence of nephritis.

Immune-Mediated Dermatologic Adverse Reactions

TECENTRIQ HYBREZA can cause immune-mediated rash or dermatitis, including Grade 3 and fatal adverse reactions. Exfoliative dermatitis, including Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), and toxic epidermal necrolysis (TEN), has occurred with PD-1/PD-L1 blocking antibodies. Topical emollients and/or topical corticosteroids may be adequate to treat mild to moderate non-exfoliative rashes. Withhold or permanently discontinue TECENTRIQ HYBREZA depending on severity [see *Dosage and Administration (2.4)*].

One fatal case of an immune-mediated dermatologic adverse reaction, due to TEN, occurred (0.4%, 1/247) in patients with locally advanced or metastatic NSCLC receiving TECENTRIQ HYBREZA as monotherapy in the IMscin001 trial [see *Adverse Reactions (6.1)*].

Other Immune-Mediated Adverse Reactions

The following clinically significant immune-mediated adverse reactions occurred at an incidence of < 1% (unless otherwise noted) in patients receiving intravenous atezolizumab or were reported with the use of other PD-1/PD-L1 blocking antibodies. Severe or fatal cases have been reported for some of these adverse reactions.

- *Cardiac/Vascular:* Myocarditis, pericarditis, vasculitis.

- *Nervous System*: Meningitis, encephalitis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis (including exacerbation), Guillain-Barré syndrome, nerve paresis, autoimmune neuropathy.
- *Ocular*: Uveitis, iritis, and other ocular inflammatory toxicities occurred. Some cases were associated with retinal detachment. Various grades of visual impairment, including blindness, occurred. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, as this may require treatment with systemic steroids to reduce the risk of permanent vision loss.
- *Gastrointestinal*: Pancreatitis to include increases in serum amylase and lipase levels, gastritis, duodenitis.
- *Musculoskeletal and Connective Tissue*: Myositis/polymyositis, rhabdomyolysis and associated sequelae including renal failure, arthritis, polymyalgia rheumatic.
- *Endocrine*: Hypoparathyroidism.
- *Hematologic/Immune*: Hemolytic anemia, aplastic anemia, hemophagocytic lymphohistiocytosis, systemic inflammatory response syndrome, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), sarcoidosis, immune thrombocytopenic purpura, solid organ transplant rejection, other transplant (including corneal graft) rejection.
- *Other*: Myocarditis-Myositis-Myasthenia Gravis (or Myasthenia-Like) Overlap Syndrome, reported as the co-occurrence of either two or all three adverse reactions.

5.2 Infusion-Related Reactions

TECENTRIQ HYBREZA can cause severe or life-threatening infusion-related reactions, including Grade 3 adverse reactions and anaphylaxis. Monitor for signs and symptoms of infusion-related reactions. Pause, slow the rate of, or permanently discontinue TECENTRIQ HYBREZA based on the severity [see *Dosage and Administration (2.4)*]. For Grade 1 or 2 infusion-related reactions, consider using pre-medications with subsequent doses.

5.3 Complications of Allogeneic HSCT after PD-1/PD-L1 Inhibitors

Fatal and other serious complications can occur in patients who receive allogeneic hematopoietic stem cell transplantation (HSCT) before or after being treated with a PD-1/PD-L1 blocking antibody. Transplant-related complications include hyperacute graft-versus-host disease (GVHD), acute GVHD, chronic GVHD, hepatic veno-occlusive disease after reduced intensity conditioning, and steroid-requiring febrile syndrome (without an identified infectious cause). These complications may occur despite intervening therapy between PD-1/PD-L1 blockage and allogeneic HSCT.

Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefits versus risks of treatment with a PD-1/PD-L1 blocking antibody prior to or after an allogeneic HSCT.

5.4 Embryo-Fetal Toxicity

Based on its mechanism of action, TECENTRIQ HYBREZA can cause fetal harm when administered to a pregnant woman. There are no available data on the use of TECENTRIQ HYBREZA in pregnant women. Animal studies have demonstrated that inhibition of the PD-L1/PD-1 pathway can lead to increased risk of immune-related rejection of the developing fetus resulting in fetal death.

Verify pregnancy status of females of reproductive potential prior to initiating TECENTRIQ HYBREZA. Advise females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TECENTRIQ HYBREZA and for 5 months after the last dose [see *Use in Specific Populations* (8.1, 8.3)].

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

- Severe and Fatal Immune-Mediated Adverse Reactions [see *Warnings and Precautions* (5.1)]
- Infusion-Related Reactions [see *Warnings and Precautions* (5.2)]
- Complications of Allogeneic HSCT after PD-1/PD-L1 Inhibitors [see *Warnings and Precautions* (5.3)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse Reactions of TECENTRIQ HYBREZA in Adult Patients with NSCLC

The safety of TECENTRIQ HYBREZA was evaluated in IMscin001, open-label, multi-center, international, randomized trial for patients with locally advanced or metastatic NSCLC who have not been exposed to cancer immunotherapy and who have had disease progression on prior platinum-based therapy [see *Clinical Studies* (14.1)]. Patients with previously treated metastatic non-small cell lung cancer (NSCLC) either received TECENTRIQ HYBREZA (containing 1,875 mg of atezolizumab and 30,000 units of hyaluronidase) administered subcutaneously into the thigh over approximately 7 minutes every 3 weeks or intravenous atezolizumab every 3 weeks until disease progression or unacceptable toxicity. Among 247 patients who received TECENTRIQ HYBREZA, 32% were exposed for 6 months or longer and 8% were exposed for greater than one year.

The median age was 64 years (range: 27 to 85); 69% male; 67% White, 22% Asian, 0.8% Black or African American; 74% were non-Hispanic or Latino; 26% had an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 74% had an ECOG PS of 1; and 70% of patients were current or previous smokers.

Serious adverse reactions occurred in 19% of patients who received TECENTRIQ HYBREZA. Serious adverse reactions (> 1%) included pneumonia, myocardial infarction, and pleural effusion. Fatal adverse reactions occurred in 6% of patients who received TECENTRIQ HYBREZA, including pneumonia (2.4%), myocardial infarction (1.2%), head injury (0.4%), ischemic stroke (0.4%), pleural effusion (0.4%), pulmonary embolism (0.4%), respiratory tract infection (0.4%), sepsis (0.4%), and toxic epidermal necrolysis (0.4%).

Permanent discontinuation of TECENTRIQ HYBREZA due to an adverse reaction occurred in 3.6% of patients. Adverse reactions which resulted in permanent discontinuation of TECENTRIQ HYBREZA in > 1% of patients included pneumonia (2%).

Dosage interruptions of TECENTRIQ HYBREZA due to an adverse reaction occurred in 32% of patients. Adverse reactions which required dosage interruption in > 1% of patients were COVID-19 (4.9%), increased aspartate aminotransferase (2.8%), increased alanine aminotransferase (2.4%), pneumonia (2.4%), anemia (1.6%), dyspnea (1.6%), fatigue (1.2%), and viral respiratory

tract infection (1.2%). The most common adverse reactions of any grade (occurring in $\geq 10\%$ of patients) were fatigue (19%), musculoskeletal pain (15%), cough (13%), dyspnea (12%), and decreased appetite (11%).

Tables 3 and 4 summarize adverse reactions and selected laboratory abnormalities, respectively in TECENTRIQ HYBREZA-treated patients in IMscin001.

Table 3: Adverse Reactions ($\geq 10\%$) in Adult Patients with Locally Advanced or Metastatic NSCLC Who Received TECENTRIQ HYBREZA in IMscin001

Adverse Reaction*	TECENTRIQ HYBREZA n = 247		Intravenous Atezolizumab n = 124	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
General Disorder and Administration Site Conditions				
Fatigue ¹	19	0.8	18	0
Musculoskeletal and Connective Tissue disorders				
Musculoskeletal Pain ²	15	0.4	13	3.2
Respiratory, Thoracic and Mediastinal				
Cough ³	13	0	7	0
Dyspnea ⁴	12	1.2	15	1.6
Metabolism and Nutrition Disorders				
Decreased appetite	11	0	11	0

* Graded per NCI CTCAE v5.0

¹ Composite term includes fatigue, asthenia

² Composite term includes back pain, myalgia, bone pain, musculoskeletal chest pain, neck pain, spinal pain, non-cardiac chest pain

³ Composite term includes cough, productive cough

⁴ Composite term includes dyspnea, dyspnea at rest, dyspnea exertional

Clinically relevant adverse reactions in $< 10\%$ of patients who received TECENTRIQ HYBREZA were local injection site reactions (4.5%) and pyrexia (1.2%).

Table 4: Select Laboratory Abnormalities ($\geq 20\%$) That Worsened from Baseline in Adult Patients with Advanced or Metastatic NSCLC Who Received TECENTRIQ HYBREZA in IMscin001

Laboratory Abnormality ¹	TECENTRIQ HYBREZA (n = 247)		Intravenous Atezolizumab (n = 124)	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
Hematology				
Decreased Hemoglobin	67	6	63	5
Decreased lymphocytes	37	9	45	15
Chemistry				
Decreased Sodium	46	3.9	47	5
Decreased Albumin	34	2.2	27	0
Increased Alkaline Phosphatase	33	1.3	27	0
Increased AST	28	2.6	32	2.6
Increased ALT	28	2.6	23	1.7
Decreased calcium	22	2.6	23	0.9
Increased calcium	20	2.6	24	1.7
Increased potassium	21	1.7	22	1.7
Increased INR	20	2	23	0
Increased Creatinine	19	1.7	26	0.9

Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: TECENTRIQ HYBREZA (48-233) and intravenous atezolizumab (19-117)

¹ Graded per NCI CTCAE v5.0

Adverse Reactions in Adult Patients with NSCLC Treated with Intravenous Atezolizumab

The safety of TECENTRIQ HYBREZA for its approved NSCLC indications [see *Indications and Usage (1.1)*] has been established in adequate and well-controlled studies of intravenous atezolizumab for the:

- adjuvant treatment (following tumor resection and platinum-based chemotherapy) in adult patients with stage II to IIIA NSCLC whose tumors have PD-L1 expression on $\geq 1\%$ of tumor cells (IMpower010 study).
- first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained $\geq 50\%$ of tumor cells [TC $\geq 50\%$] or PD-L1 stained tumor-infiltrating immune cells [IC] covering $\geq 10\%$ of the tumor area [IC $\geq 10\%$]), with no EGFR or ALK genomic tumor aberrations (IMpower110 study).
- first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations (IMpower150 study).
- first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations (IMpower130 study).
- first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression, with no EGFR or ALK genomic tumor aberrations (OAK study).

Below is a description of adverse reactions of intravenous atezolizumab in these adequate and well-controlled NSCLC studies.

Non-Small Cell Lung Cancer (NSCLC)

Adjuvant Treatment of Early-stage NSCLC

IMpower010

The safety of intravenous atezolizumab was evaluated in IMpower010, a multicenter, open-label, randomized trial for the adjuvant treatment of patients with stage IB (tumors ≥ 4 cm) -IIIA NSCLC who had complete tumor resection and received up to 4 cycles of cisplatin-based adjuvant chemotherapy. Patients received intravenous atezolizumab 1200 mg every 3 weeks (n = 495) for 1 year (16 cycles), unless disease progression or unacceptable toxicity occurred, or best supportive care [see *Clinical Studies (14.1)*]. The median number of cycles received was 16 (range: 1, 16).

Fatal adverse reactions occurred in 1.8% of patients receiving intravenous atezolizumab; these included multiple organ dysfunction syndrome, pneumothorax, interstitial lung disease, arrhythmia, acute cardiac failure, myocarditis, cerebrovascular accident, death of unknown cause, and acute myeloid leukemia (1 patient each).

Serious adverse reactions occurred in 18% of patients receiving intravenous atezolizumab. The most frequent serious adverse reactions ($> 1\%$) were pneumonia (1.8%), pneumonitis (1.6%), and pyrexia (1.2%).

Intravenous atezolizumab was discontinued due to adverse reactions in 18% of patients; the most common adverse reactions ($\geq 1\%$) leading to intravenous atezolizumab discontinuation were pneumonitis (2.2%), hypothyroidism (1.6%), increased aspartate aminotransferase (1.4%), arthralgia (1.0%), and increased alanine aminotransferase (1.0%).

Adverse reactions leading to interruption of intravenous atezolizumab occurred in 29% of patients; the most common ($> 1\%$) were rash (3.0%), hyperthyroidism (2.8%), hypothyroidism (1.6%), increased AST (1.6%), pyrexia (1.6%), increased ALT (1.4%), upper respiratory tract infection (1.4%), headache (1.2%), peripheral neuropathy (1.2%), and pneumonia (1.2%).

Tables 5 and 6 summarize adverse reactions and selected laboratory abnormalities in patients receiving intravenous atezolizumab in IMpower010.

Table 5: Adverse Reactions Occurring in $\geq 10\%$ of Patients with Early-Stage NSCLC Receiving Intravenous Atezolizumab in IMpower010

Adverse Reaction*	Intravenous Atezolizumab N = 495		Best Supportive Care N = 495	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
Skin and Subcutaneous Tissue				
Rash ¹	17	1.2	1.4	0
Pruritus	10	0	0.6	0
Endocrine Disorders				
Hypothyroidism ²	14	0	0.6	0
Respiratory, Thoracic and Mediastinal				
Cough ³	16	0	11	0
General				
Pyrexia ⁴	14	0.8	2.2	0.2
Fatigue ⁵	14	0.6	5	0.2
Nervous System Disorders				
Peripheral neuropathy ⁶	12	0.4	7	0.2
Musculoskeletal and Connective Tissue				
Musculoskeletal pain ⁷	14	0.8	9	0.2
Arthralgia ⁸	11	0.6	6	0

* Graded per NCI CTCAE v4.0

¹ Includes rash, dermatitis, genital rash, skin exfoliation, rash maculo-papular, rash erythematous, rash papular, lichen planus, eczema asteatotic, dermatitis exfoliative, palmar-plantar erythrodysesthesia syndrome, dyshidrotic eczema, eczema, drug eruption, rash pruritic, toxic skin eruption, dermatitis acneiform

² Includes hypothyroidism, autoimmune hypothyroidism, primary hypothyroidism, blood thyroid stimulating hormone increased

³ Productive cough, upper airway cough syndrome, cough

⁴ Includes pyrexia, body temperature increased, hyperthermia

⁵ Includes fatigue, asthenia

⁶ Includes paraesthesia, neuropathy peripheral, peripheral sensory neuropathy, hypoaesthesia, polyneuropathy, dysaesthesia, neuralgia, axonal neuropathy

⁷ Includes myalgia, bone pain, back pain, spinal pain, musculoskeletal chest pain, pain in extremity, neck pain, non-cardiac chest pain, musculoskeletal discomfort, musculoskeletal stiffness, musculoskeletal pain

⁸ Includes arthralgia, arthritis

Table 6: Laboratory Abnormalities Worsening from Baseline Occurring in $\geq 20\%$ of Patients with Early-Stage NSCLC Receiving Intravenous Atezolizumab in IMpower10

Laboratory Abnormality ¹	Intravenous Atezolizumab ²		Best Supportive Care ²	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
Chemistry				
Increased aspartate aminotransferase	34	2.5	18	0
Increased alanine aminotransferase	30	3.3	19	0.4
Hyperkalemia	24	3.5	15	2.5
Increased blood creatinine	31	0.2	23	0.2

¹ Graded per NCI CTCAE v4.0, except for increased creatinine which only includes patients with creatinine increase based on upper limit of normal definition for Grade 1 events (NCI CTCAE v5.0).

² The denominators used to calculate the rate varied from 78–480 for BSC arm and 483 for intravenous atezolizumab are for all tests of interest based on the number of patients with a baseline value and at least one post-treatment value.

Metastatic Chemotherapy-Naïve NSCLC

IMpower110

The safety of intravenous atezolizumab was evaluated in IMpower110, a multicenter, international, randomized, open-label study in 549 chemotherapy-naïve patients with stage IV NSCLC, including those with EGFR or ALK genomic tumor aberrations. Patients received intravenous atezolizumab 1200 mg every 3 weeks (n = 286) or platinum-based chemotherapy consisting of carboplatin or cisplatin with either pemetrexed or gemcitabine (n = 263) until disease progression or unacceptable toxicity [see *Clinical Studies (14.1)*]. IMpower110 enrolled patients whose tumors express PD-L1 (PD-L1 stained $\geq 1\%$ of tumor cells [TC] or PD-L1 stained tumor-infiltrating immune cells [IC] covering $\geq 1\%$ of the tumor area). The median duration of exposure to intravenous atezolizumab was 5.3 months (0 to 33 months).

Fatal adverse reactions occurred in 3.8% of patients receiving intravenous atezolizumab; these included death (reported as unexplained death and death of unknown cause), aspiration, chronic obstructive pulmonary disease, pulmonary embolism, acute myocardial infarction, cardiac arrest, mechanical ileus, sepsis, cerebral infarction, and device occlusion (1 patient each).

Serious adverse reactions occurred in 28% of patients receiving intravenous atezolizumab. The most frequent serious adverse reactions ($> 2\%$) were pneumonia (2.8%), chronic obstructive pulmonary disease (2.1%) and pneumonitis (2.1%).

Intravenous atezolizumab was discontinued due to adverse reactions in 6% of patients; the most common adverse reactions (≥ 2 patients) leading to intravenous atezolizumab discontinuation were peripheral neuropathy and pneumonitis.

Adverse reactions leading to interruption of intravenous atezolizumab occurred in 26% of patients; the most common ($> 1\%$) were ALT increased (2.1%), AST increased (2.1%), pneumonitis (2.1%), pyrexia (1.4%), pneumonia (1.4%) and upper respiratory tract infection (1.4%).

Tables 7 and 8 summarize adverse reactions and selected laboratory abnormalities in patients receiving intravenous atezolizumab in IMpower110.

Table 7: Adverse Reactions Occurring in $\geq 10\%$ of Patients with NSCLC Receiving Intravenous Atezolizumab in IMpower110

Adverse Reaction	Intravenous Atezolizumab N = 286		Platinum-Based Chemotherapy N = 263	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
Gastrointestinal				
Nausea	14	0.3	34	1.9
Constipation	12	1.0	22	0.8
Diarrhea	11	0	12	0.8
General				
Fatigue/Asthenia	25	1.4	34	4.2
Pyrexia	14	0	9	0.4
Metabolism and Nutrition				
Decreased appetite	15	0.7	19	0
Respiratory, Thoracic and Mediastinal				
Dyspnea	14	0.7	10	0
Cough	12	0.3	10	0

Graded per NCI CTCAE v4.0

Table 8: Laboratory Abnormalities Worsening from Baseline Occurring in $\geq 20\%$ of Patients Receiving Intravenous Atezolizumab in IMpower110

Laboratory Abnormality	Intravenous Atezolizumab		Platinum-Based Chemotherapy	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
Hematology				
Anemia	69	1.8	94	20
Lymphopenia	47	9	59	17
Chemistry				
Hypoalbuminemia	48	0.4	39	2
Increased alkaline phosphatase	46	2.5	42	1.2
Hyponatremia	44	9	36	7
Increased ALT	38	3.2	32	0.8
Increased AST	36	3.2	32	0.8
Hyperkalemia	29	3.9	36	2.7
Hypocalcemia	24	1.4	24	2.7
Increased blood creatinine	24	0.7	33	1.5
Hypophosphatemia	23	3.6	21	2

Each test incidence is based on the number of patients who had at least one on-study laboratory measurement available: intravenous atezolizumab (range: 278–281); platinum-based chemotherapy (range: 256–260). Graded per NCI CTCAE v4.0. Increased blood creatinine only includes patients with test results above the normal range.

First-Line Metastatic Non-squamous NSCLC

IMpower150

The safety of intravenous atezolizumab with bevacizumab, paclitaxel and carboplatin was evaluated in IMpower150, a multicenter, international, randomized, open-label trial in which 393 chemotherapy-naïve patients with metastatic non-squamous NSCLC received intravenous atezolizumab 1200 mg with bevacizumab 15 mg/kg, paclitaxel 175 mg/m² or 200 mg/m², and carboplatin AUC 6 mg/mL/min intravenously every 3 weeks for a maximum of 4 or 6 cycles, followed by intravenous atezolizumab 1200 mg with bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity [see *Clinical Studies (14.1)*]. The median duration of exposure to intravenous atezolizumab was 8.3 months in patients receiving intravenous atezolizumab with bevacizumab, paclitaxel, and carboplatin.

Fatal adverse reactions occurred in 6% of patients receiving intravenous atezolizumab; these included hemoptysis, febrile neutropenia, pulmonary embolism, pulmonary hemorrhage, death, cardiac arrest, cerebrovascular accident, pneumonia, aspiration pneumonia, chronic obstructive pulmonary disease, intracranial hemorrhage, intestinal angina, intestinal ischemia, intestinal obstruction and aortic dissection.

Serious adverse reactions occurred in 44%. The most frequent serious adverse reactions (> 2%) were febrile neutropenia, pneumonia, diarrhea, and hemoptysis.

Intravenous atezolizumab was discontinued due to adverse reactions in 15% of patients; the most common adverse reaction leading to discontinuation was pneumonitis (1.8%).

Adverse reactions leading to interruption of intravenous atezolizumab occurred in 48%; the most common (> 1%) were neutropenia, thrombocytopenia, fatigue/asthenia, diarrhea, hypothyroidism, anemia, pneumonia, pyrexia, hyperthyroidism, febrile neutropenia, increased ALT, dyspnea, dehydration and proteinuria.

Tables 9 and 10 summarize adverse reactions and laboratory abnormalities in patients receiving intravenous atezolizumab with bevacizumab, paclitaxel, and carboplatin in IMpower150.

Table 9: Adverse Reactions Occurring in ≥ 15% of Patients with NSCLC Receiving Intravenous Atezolizumab in IMpower150

Adverse Reaction	Intravenous Atezolizumab with Bevacizumab, Paclitaxel, and Carboplatin N = 393		Bevacizumab, Paclitaxel and Carboplatin N = 394	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
Nervous System				
Neuropathy ¹	56	3	47	3
Headache	16	0.8	13	0
General				
Fatigue/Asthenia	50	6	46	6
Pyrexia	19	0.3	9	0.5
Skin and Subcutaneous Tissue				
Alopecia	48	0	46	0
Rash ²	23	2	10	0.3
Musculoskeletal and Connective Tissue				
Myalgia/Pain ³	42	3	34	2
Arthralgia	26	1	22	1
Gastrointestinal				
Nausea	39	4	32	2
Diarrhea ⁴	33	6	25	0.5
Constipation	30	0.3	23	0.3
Vomiting	19	2	18	1
Metabolism and Nutrition				
Decreased appetite	29	4	21	0.8
Vascular				
Hypertension	25	9	22	8
Respiratory				
Cough	20	0.8	19	0.3
Epistaxis	17	1	22	0.3

Adverse Reaction	Intravenous Atezolizumab with Bevacizumab, Paclitaxel, and Carboplatin N = 393		Bevacizumab, Paclitaxel and Carboplatin N = 394	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
Renal				
Proteinuria ⁵	16	3	15	3

Graded per NCI CTCAE v4.0

¹ Includes neuropathy peripheral, peripheral sensory neuropathy, hypoesthesia, paresthesia, dysesthesia, polyneuropathy

² Includes rash, rash maculo-papular, drug eruption, eczema, eczema asteatotic, dermatitis, contact dermatitis, rash erythematous, rash macular, pruritic rash, seborrheic dermatitis, dermatitis psoriasiform

³ Includes pain in extremity, musculoskeletal chest pain, musculoskeletal discomfort, neck pain, back pain, myalgia, and bone pain

⁴ Includes diarrhea, gastroenteritis, colitis, enterocolitis

⁵ Based on adverse reaction terms since laboratory data for proteinuria was not systematically collected

Table 10: Laboratory Abnormalities Worsening from Baseline Occurring in ≥ 20% of Patients with NSCLC Receiving Intravenous Atezolizumab in IMpower150

Laboratory Abnormality	Intravenous Atezolizumab with Bevacizumab, Paclitaxel, and Carboplatin		Bevacizumab, Paclitaxel and Carboplatin	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
Hematology				
Anemia	83	10	83	9
Neutropenia	52	31	45	26
Lymphopenia	48	17	38	13
Chemistry				
Hyperglycemia	61	0	60	0
Increased BUN	52	NA ¹	44	NA ¹
Hypomagnesemia	42	2	36	1
Hypoalbuminemia	40	3	31	2
Increased AST	40	4	28	0.8
Hyponatremia	38	10	36	9
Increased Alkaline Phosphatase	37	2	32	1
Increased ALT	37	6	28	0.5
Increased TSH	30	NA ¹	20	NA ¹
Hyperkalemia	28	3	25	2
Increased Creatinine	28	1	19	2
Hypocalcemia	26	3	21	3
Hypophosphatemia	25	4	18	4
Hypokalemia	23	7	14	4

Laboratory Abnormality	Intravenous Atezolizumab with Bevacizumab, Paclitaxel, and Carboplatin		Bevacizumab, Paclitaxel and Carboplatin	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
Hyperphosphatemia	25	NA ¹	19	NA ¹

Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: Intravenous Atezolizumab with bevacizumab, paclitaxel, and carboplatin range: (337–380); bevacizumab, paclitaxel, and carboplatin (range: 337–382). Graded per NCI CTCAE v4.0

¹ NA = Not applicable. NCI CTCAE does not provide a Grades 3–4 definition for these laboratory abnormalities

IMpower130

The safety of intravenous atezolizumab with paclitaxel protein-bound and carboplatin was evaluated in IMpower130, a multicenter, international, randomized, open-label trial in which 473 chemotherapy-naïve patients with metastatic non-squamous NSCLC received intravenous atezolizumab 1200 mg and carboplatin AUC 6 mg/mL/min intravenously on Day 1 and paclitaxel protein-bound 100 mg/m² intravenously on Days 1, 8, and 15 of each 21-day cycle for a maximum of 4 or 6 cycles, followed by intravenous atezolizumab 1200 mg intravenously every 3 weeks until disease progression or unacceptable toxicity [see *Clinical Studies (14.1)*]. Among patients receiving intravenous atezolizumab, 55% were exposed for 6 months or longer and 3.5% were exposed for greater than one year.

Fatal adverse reactions occurred in 5.3% of patients receiving intravenous atezolizumab; these included pneumonia (1.1%), pulmonary embolism (0.8%), myocardial infarction (0.6%), cardiac arrest (0.4%), pneumonitis (0.4%) and sepsis, septic shock, staphylococcal sepsis, aspiration, respiratory distress, cardiorespiratory arrest, ventricular tachycardia, death (not otherwise specified), and hepatic cirrhosis (0.2% each).

Serious adverse reactions occurred in 51% of patients receiving intravenous atezolizumab. The most frequent serious adverse reactions (≥ 2%) were pneumonia (6%), diarrhea (3%), lung infection (3%), pulmonary embolism (3%), chronic obstructive pulmonary disease exacerbation (2.5%), dyspnea (2.3%), and febrile neutropenia (1.9%).

Intravenous atezolizumab was discontinued due to adverse reactions in 13% of patients; the most common adverse reactions leading to discontinuation were pneumonia (0.8%), pulmonary embolism (0.8%), fatigue (0.6%), dyspnea (0.6%), pneumonitis (0.6%), neutropenia (0.4%), nausea (0.4%), renal failure (0.4%), cardiac arrest (0.4%), and septic shock (0.4%).

Adverse reactions leading to interruption of intravenous atezolizumab occurred in 62% of patients; the most common (> 1%) were neutropenia, thrombocytopenia, anemia, diarrhea, fatigue/asthenia, pneumonia, dyspnea, pneumonitis, pyrexia, nausea, acute kidney injury, vomiting, pulmonary embolism, arthralgia, infusion-related reaction, abdominal pain, chronic obstructive pulmonary disease exacerbation, dehydration, and hypokalemia.

Tables 11 and 12 summarize adverse reactions and laboratory abnormalities in patients receiving intravenous atezolizumab with paclitaxel protein-bound and carboplatin in IMpower130.

Table 11: Adverse Reactions Occurring in $\geq 20\%$ of Patients with NSCLC Receiving Intravenous Atezolizumab in IMpower130

Adverse Reaction	Intravenous Atezolizumab with Paclitaxel Protein-Bound and Carboplatin N = 473		Paclitaxel Protein-Bound and Carboplatin N = 232	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
General				
Fatigue/Asthenia	61	11	60	8
Gastrointestinal				
Nausea	50	3.4	46	2.2
Diarrhea ¹	43	6	32	6
Constipation	36	1.1	31	0
Vomiting	27	2.7	19	2.2
Musculoskeletal and Connective Tissue				
Myalgia/Pain ²	38	3	22	0.4
Nervous System				
Neuropathy ³	33	2.5	28	2.2
Respiratory, Thoracic and Mediastinal				
Dyspnea ⁴	32	4.9	25	1.3
Cough	27	0.6	17	0
Skin and Subcutaneous Tissue				
Alopecia	32	0	27	0
Rash ⁵	20	0.6	11	0.9
Metabolism and Nutrition				
Decreased appetite	30	2.1	26	2.2

Graded per NCI CTCAE v4.0

¹ Includes diarrhea, colitis, and gastroenteritis

² Includes back pain, pain in extremity, myalgia, musculoskeletal chest pain, bone pain, neck pain and musculoskeletal discomfort

³ Includes neuropathy peripheral, peripheral sensory neuropathy, hypoesthesia, paresthesia, dysesthesia, polyneuropathy

⁴ Includes dyspnea, dyspnea exertional and wheezing

⁵ Includes rash, rash maculo-papular, eczema, rash pruritic, rash erythematous, dermatitis, dermatitis contact, drug eruption, seborrheic dermatitis and rash macular

Table 12: Laboratory Abnormalities Worsening from Baseline Occurring in ≥ 20% of Patients Receiving Intravenous Atezolizumab in IMpower130

Laboratory Abnormality	Intravenous Atezolizumab with Paclitaxel Protein-Bound and Carboplatin N = 473		Paclitaxel Protein-Bound and Carboplatin N = 232	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
Hematology				
Anemia	92	33	87	25
Neutropenia	75	50	67	39
Thrombocytopenia	73	19	59	13
Lymphopenia	71	23	61	16
Chemistry				
Hyperglycemia	75	8	66	8
Hypomagnesemia	50	3.4	42	3.2
Hyponatremia	37	9	28	7
Hypoalbuminemia	35	1.3	31	0
Increased ALT	31	2.8	24	3.9
Hypocalcemia	31	2.6	27	1.8
Hypophosphatemia	29	6	20	3.2
Increased AST	28	2.2	24	1.8
Increased TSH	26	NA ¹	5	NA ¹
Hypokalemia	26	6	24	4.4
Increased Alkaline Phosphatase	25	2.6	22	1.3
Increased Blood Creatinine	23	2.8	16	0.4
Hyperphosphatemia	21	NA ¹	13	NA ¹

Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous atezolizumab with paclitaxel protein-bound and carboplatin (range: 423–467); paclitaxel protein-bound and carboplatin (range: 218–229). Graded per NCI CTCAE v4.0.

¹ NA = Not applicable. NCI CTCAE does not provide a Grades 3–4 definition for these laboratory abnormalities

Previously Treated Metastatic NSCLC

OAK

The safety of intravenous atezolizumab was evaluated in OAK, a multicenter, international, randomized, open-label trial in patients with metastatic NSCLC who progressed during or following a platinum-containing regimen, regardless of PD-L1 expression [see *Clinical Studies (14.1)*]. A total of 609 patients received intravenous atezolizumab 1200 mg intravenously every 3 weeks until unacceptable toxicity, radiographic progression, or clinical progression or docetaxel (n = 578) 75 mg/m² intravenously every 3 weeks until unacceptable toxicity or disease progression. The study excluded patients with active or prior autoimmune disease or with medical conditions that required systemic corticosteroids. The median duration of exposure was

3.4 months (0 to 26 months) in intravenous atezolizumab-treated patients and 2.1 months (0 to 23 months) in docetaxel-treated patients.

The study population characteristics were: median age of 63 years (25 to 85 years), 46% age 65 years or older, 62% male, 71% White, 20% Asian, 68% former smoker, 16% current smoker, and 63% had Eastern Cooperative Oncology Group (ECOG) performance status of 1.

Fatal adverse reactions occurred in 1.6% of patients; these included pneumonia, sepsis, septic shock, dyspnea, pulmonary hemorrhage, sudden death, myocardial ischemia or renal failure.

Serious adverse reactions occurred in 33.5% of patients. The most frequent serious adverse reactions (> 1%) were pneumonia, sepsis, dyspnea, pleural effusion, pulmonary embolism, pyrexia and respiratory tract infection.

Intravenous atezolizumab was discontinued due to adverse reactions in 8% of patients. The most common adverse reactions leading to intravenous atezolizumab discontinuation were fatigue, infections and dyspnea. Adverse reactions leading to interruption of intravenous atezolizumab occurred in 25% of patients; the most common (> 1%) were pneumonia, liver function test abnormality, dyspnea, fatigue, pyrexia, and back pain.

Tables 13 and 14 summarize adverse reactions and laboratory abnormalities, respectively, in OAK.

Table 13: Adverse Reactions Occurring in ≥ 10% of Patients with NSCLC Receiving Intravenous Atezolizumab in OAK

Adverse Reaction	Intravenous Atezolizumab N = 609		Docetaxel N = 578	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
General				
Fatigue/Asthenia ¹	44	4	53	6
Pyrexia	18	< 1	13	< 1
Respiratory				
Cough ²	26	< 1	21	< 1
Dyspnea	22	2.8	21	2.6
Metabolism and Nutrition				
Decreased appetite	23	< 1	24	1.6
Musculoskeletal				
Myalgia/Pain ³	20	1.3	20	< 1
Arthralgia	12	0.5	10	0.2
Gastrointestinal				
Nausea	18	< 1	23	< 1
Constipation	18	< 1	14	< 1
Diarrhea	16	< 1	24	2
Skin				
Rash ⁴	12	< 1	10	0

Graded per NCI CTCAE v4.0

¹ Includes fatigue and asthenia

² Includes cough and exertional cough

³ Includes musculoskeletal pain, musculoskeletal stiffness, musculoskeletal chest pain, myalgia

⁴ Includes rash, erythematous rash, generalized rash, maculopapular rash, papular rash, pruritic rash, pustular rash, pemphigoid

Table 14: Laboratory Abnormalities Worsening from Baseline Occurring in $\geq 20\%$ of Patients with NSCLC Receiving Intravenous Atezolizumab in OAK

Laboratory Abnormality	Intravenous Atezolizumab		Docetaxel	
	All Grades (%)	Grades 3-4 (%)	All Grades (%)	Grades 3-4 (%)
Hematology				
Anemia	67	3	82	7
Lymphocytopenia	49	14	60	21
Chemistry				
Hypoalbuminemia	48	4	50	3
Hyponatremia	42	7	31	6
Increased Alkaline Phosphatase	39	2	25	1
Increased AST	31	3	16	0.5
Increased ALT	27	3	14	0.5
Hypophosphatemia	27	5	23	4
Hypomagnesemia	26	1	21	1
Increased Creatinine	23	2	16	1

Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous atezolizumab (range: 546–585) and docetaxel (range: 532–560). Graded according to NCI CTCAE version 4.0

Adverse Reactions in Adult Patients with Small Cell Lung Cancer

The safety of TECENTRIQ HYBREZA for its approved Small Cell Lung Cancer (SCLC) indications [see *Indications and Usage (1.2)*] has been established in adequate and well-controlled studies of intravenous atezolizumab for SCLC (IMpower133 and IMforte studies).

Small Cell Lung Cancer (SCLC)

IMpower133

The safety of intravenous atezolizumab with carboplatin and etoposide was evaluated in IMpower133, a randomized, multicenter, double-blind, placebo-controlled trial in which 198 patients with ES-SCLC received intravenous atezolizumab 1200 mg and carboplatin AUC 5 mg/mL/min on Day 1 and etoposide 100 mg/m² intravenously on Days 1, 2 and 3 of each 21-day cycle for a maximum of 4 cycles, followed by intravenous atezolizumab 1200 mg every 3 weeks until disease progression or unacceptable toxicity [see *Clinical Studies (14.2)*]. Among 198 patients receiving intravenous atezolizumab, 32% were exposed for 6 months or longer and 12% were exposed for 12 months or longer.

Fatal adverse reactions occurred in 2% of patients receiving intravenous atezolizumab. These included pneumonia, respiratory failure, neutropenia, and death (1 patient each).

Serious adverse reactions occurred in 37% of patients receiving intravenous atezolizumab. Serious adverse reactions in > 2% were pneumonia (4.5%), neutropenia (3.5%), febrile neutropenia (2.5%), and thrombocytopenia (2.5%).

Intravenous atezolizumab was discontinued due to adverse reactions in 11% of patients. The most frequent adverse reaction requiring permanent discontinuation in > 2% of patients was infusion-related reactions (2.5%).

Adverse reactions leading to interruption of intravenous atezolizumab occurred in 59% of patients; the most common (> 1%) were neutropenia (22%), anemia (9%), leukopenia (7%), thrombocytopenia (5%), fatigue (4.0%), infusion-related reaction (3.5%), pneumonia (2.0%), febrile neutropenia (1.5%), increased ALT (1.5%), and nausea (1.5%).

Tables 15 and 16 summarize adverse reactions and laboratory abnormalities, respectively, in patients who received intravenous atezolizumab with carboplatin and etoposide in IMpower133.

Table 15: Adverse Reactions Occurring in ≥ 20% of Patients with SCLC Receiving Intravenous Atezolizumab in IMpower133

Adverse Reaction	Intravenous Atezolizumab with Carboplatin and Etoposide N = 198		Placebo with Carboplatin and Etoposide N = 196	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
General				
Fatigue/Asthenia	39	5	33	3
Gastrointestinal				
Nausea	38	1	33	1
Constipation	26	1	30	1
Vomiting	20	2	17	3
Skin and Subcutaneous Tissue				
Alopecia	37	0	35	0
Metabolism and Nutrition				
Decreased appetite	27	1	18	0

Graded per NCI CTCAE v4.0

Table 16: Laboratory Abnormalities Worsening from Baseline Occurring in ≥ 20% of Patients with SCLC Receiving Intravenous Atezolizumab in IMpower133

Laboratory Abnormality	Intravenous Atezolizumab with Carboplatin and Etoposide		Placebo with Carboplatin and Etoposide	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
Hematology				
Anemia	94	17	93	19
Neutropenia	73	45	76	48
Thrombocytopenia	58	20	53	17

Laboratory Abnormality	Intravenous Atezolizumab with Carboplatin and Etoposide		Placebo with Carboplatin and Etoposide	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
Lymphopenia	46	14	38	11
Chemistry				
Hyperglycemia	67	10	65	8
Increased Alkaline Phosphatase	38	1	35	2
Hyponatremia	34	15	33	11
Hypoalbuminemia	32	1	30	0
Decreased TSH ²	28	NA ¹	15	NA ¹
Hypomagnesemia	31	5	35	6
Hypocalcemia	26	3	28	5
Increased ALT	26	3	31	1
Increased AST	22	1	21	2
Increased Blood Creatinine	22	4	15	1
Hyperphosphatemia	21	NA ¹	23	NA ¹
Increased TSH ²	21	NA ¹	7	NA ¹

Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: Intravenous Atezolizumab (range: 181–193); Placebo (range: 181–196). Graded per NCI CTCAE v4.0

¹ NA = Not applicable

² TSH = thyroid-stimulating hormone. NCI CTCAE v4.0 does not include these laboratories.

IMforte

The safety of intravenous atezolizumab in combination with lurbinectedin was evaluated in IMforte [see *Clinical Studies (14.2)*]. Patients received intravenous atezolizumab 1200 mg IV and lurbinectedin 3.2 mg/m² IV, on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity. Primary prophylaxis of G-CSF was administered to 84% of patients. Among 242 patients receiving intravenous atezolizumab with lurbinectedin, the median duration of exposure to intravenous atezolizumab was 4.2 months, with 34% of patients exposed for 6 months or longer and 8% of patients exposed for 12 months or longer.

Serious adverse reactions occurred in 31% of patients receiving intravenous atezolizumab with lurbinectedin. Serious adverse reactions in >2% of patients were pneumonia (2.5%), respiratory tract infection (2.1%), dyspnea (2.1%), and decreased platelet count (2.1%).

Fatal adverse reactions occurred in 5% of patients receiving intravenous atezolizumab with lurbinectedin including pneumonia (3 patients), sepsis (3 patients), cardio-respiratory arrest (2 patients), myocardial infarction (2 patients), and febrile neutropenia (1 patient).

Permanent discontinuation of intravenous atezolizumab due to an adverse reaction occurred in 2.5% of patients. The adverse reactions requiring permanent discontinuation in ≥ 1% of patients who received intravenous atezolizumab were immune-mediated nephritis, peripheral neuropathy, nephropathy, pneumonitis, anemia, neutropenia, and thrombocytopenia.

Dosage interruptions of intravenous atezolizumab due to an adverse reaction occurred in 29% of patients. Adverse reactions which required dosage interruption in ≥ 2% of patients included anemia, fatigue, decreased neutrophil count, pneumonitis, and decreased platelet count.

Tables 17 and 18 summarize adverse reactions and laboratory abnormalities, respectively, in patients who received intravenous atezolizumab with lurbinectedin in IMforte.

Table 17: Adverse Reactions (≥10%) in Patients with ES-SCLC Who Received Intravenous Atezolizumab with Lurbinectedin in IMforte

Adverse Reaction	Intravenous Atezolizumab with Lurbinectedin N = 242		Intravenous Atezolizumab N = 240	
	All Grades (%)	Grades 3 or 4 (%)	All Grades (%)	Grades 3 or 4 (%)
Gastrointestinal				
Nausea	36	3	4	1
Diarrhea ¹	15	0	8	0
Vomiting	14	1	3	0
Constipation	12	0	6	1
General disorders and administration site conditions				
Fatigue ²	32	5	13	2
Musculoskeletal and connective tissue disorders				
Musculoskeletal Pain ³	19	2	16	1
Metabolism and Nutrition				
Decreased appetite	17	0	7	0
Respiratory, thoracic and mediastinal disorders				
Cough ⁴	12	0	8	0
Dyspnea ⁵	11	2	10	2

Graded per NCI CTCAE v5.0

¹ Includes diarrhea and colitis.

² Includes fatigue and asthenia.

³ Includes arthralgia, arthritis, back pain, bone pain, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain, myalgia, neck pain, non-cardiac chest pain, and pain in extremity.

⁴ Includes cough, productive cough, and upper-airway cough syndrome.

⁵ Includes dyspnea and dyspnea exertional.

Clinically relevant adverse reactions in < 10% of patients who received intravenous atezolizumab in combination with lurbinectedin included pneumonia, phlebitis, extravasation resulting in skin necrosis, hypersensitivity and increased creatine phosphokinase.

Table 18: Select Laboratory Abnormalities ($\geq 20\%$) That Worsened from Baseline in Patients with ES-SCLC Who Received Intravenous Atezolizumab in Combination with Lurbinectedin in IMforte

Laboratory Abnormality	Intravenous Atezolizumab with Lurbinectedin N = 242		Intravenous Atezolizumab N = 240	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
Hematology				
Lymphopenia	55	17	31	11
Thrombocytopenia	54	15	15	3
Anemia	51	13	12	3
Neutropenia	36	18	7	4
Chemistry				
Increased alkaline phosphatase	29	1	14	0
Decreased sodium	27	4	30	5
Increased ALT	25	3	18	2
Increased AST	24	3	22	1
Decreased calcium	24	3	8	1
Increased creatinine	21	3	14	0

Graded per NCI CTCAE v5.0

Adverse Reactions in Adult Patients with Hepatocellular Carcinoma

The safety of TECENTRIQ HYBREZA for its approved indication hepatocellular carcinoma [see *Indications and Usage (1.3)*] has been established in adequate and well-controlled studies of intravenous atezolizumab for hepatocellular carcinoma (IMbrave150 study).

Hepatocellular Carcinoma

IMbrave150

The safety of intravenous atezolizumab in combination with bevacizumab was evaluated in IMbrave150, a multicenter, international, randomized, open-label trial in patients with locally advanced or metastatic or unresectable hepatocellular carcinoma who have not received prior systemic treatment [see *Clinical Studies (14.3)*]. Patients received 1,200 mg of intravenous atezolizumab intravenously followed by 15 mg/kg bevacizumab (n = 329) every 3 weeks, or 400 mg of sorafenib (n = 156) given orally twice daily, until disease progression or unacceptable toxicity. The median duration of exposure to intravenous atezolizumab was 7.4 months (range: 0–16 months) and to bevacizumab was 6.9 months (range: 0–16 months).

Fatal adverse reactions occurred in 4.6% of patients in the intravenous atezolizumab and bevacizumab arm. The most common adverse reactions leading to death were gastrointestinal and esophageal varices hemorrhage (1.2%) and infections (1.2%).

Serious adverse reactions occurred in 38% of patients in the intravenous atezolizumab and bevacizumab arm. The most frequent serious adverse reactions ($\geq 2\%$) were gastrointestinal hemorrhage (7%), infections (6%), and pyrexia (2.1%).

Adverse reactions leading to discontinuation of intravenous atezolizumab occurred in 9% of patients in the intravenous atezolizumab and bevacizumab arm. The most common adverse reactions leading to intravenous atezolizumab discontinuation were hemorrhages (1.2%), including gastrointestinal, subarachnoid, and pulmonary hemorrhages; increased transaminases

or bilirubin (1.2%); infusion-related reaction/cytokine release syndrome (0.9%); and autoimmune hepatitis (0.6%).

Adverse reactions leading to interruption of intravenous atezolizumab occurred in 41% of patients in the intravenous atezolizumab and bevacizumab arm; the most common ($\geq 2\%$) were liver function laboratory abnormalities including increased transaminases, bilirubin, or alkaline phosphatase (8%); infections (6%); gastrointestinal hemorrhages (3.6%); thrombocytopenia/decreased platelet count (3.6%); hyperthyroidism (2.7%); and pyrexia (2.1%).

Immune-related adverse reactions requiring systemic corticosteroid therapy occurred in 12% of patients in the intravenous atezolizumab and bevacizumab arm.

Tables 19 and 20 summarize adverse reactions and laboratory abnormalities, respectively, in patients who received intravenous atezolizumab and bevacizumab in IMbrave150.

Table 19: Adverse Reactions Occurring in $\geq 10\%$ of Patients with HCC Receiving Intravenous Atezolizumab in IMbrave150

Adverse Reaction	Intravenous Atezolizumab in combination with Bevacizumab (n = 329)		Sorafenib (n = 156)	
	All Grades ² (%)	Grades 3–4 ² (%)	All Grades ² (%)	Grades 3–4 ² (%)
Vascular Disorders				
Hypertension	30	15	24	12
General Disorders and Administration Site Conditions				
Fatigue/Asthenia ¹	26	2	32	6
Pyrexia	18	0	10	0
Renal and Urinary Disorders				
Proteinuria	20	3	7	0.6
Investigations				
Weight Decreased	11	0	10	0
Skin and Subcutaneous Tissue Disorders				
Pruritus	19	0	10	0
Rash	12	0	17	2.6
Gastrointestinal Disorders				
Diarrhea	19	1.8	49	5
Constipation	13	0	14	0
Abdominal Pain	12	0	17	0
Nausea	12	0	16	0
Vomiting	10	0	8	0
Metabolism and Nutrition Disorders				
Decreased Appetite	18	1.2	24	3.8
Respiratory, Thoracic and Mediastinal Disorders				
Cough	12	0	10	0

Adverse Reaction	Intravenous Atezolizumab in combination with Bevacizumab (n = 329)		Sorafenib (n = 156)	
	All Grades ² (%)	Grades 3–4 ² (%)	All Grades ² (%)	Grades 3–4 ² (%)
Epistaxis	10	0	4.5	0
Injury, Poisoning and Procedural Complications				
Infusion-Related Reaction	11	2.4	0	0

¹ Includes fatigue and asthenia

² Graded per NCI CTCAE v4.0

Table 20: Laboratory Abnormalities Worsening from Baseline Occurring in $\geq 20\%$ of Patients with HCC Receiving Intravenous Atezolizumab in IMbrave150

Laboratory Abnormality	Intravenous Atezolizumab in combination with Bevacizumab (n = 329)		Sorafenib (n = 156)	
	All Grades ¹ (%)	Grades 3–4 ¹ (%)	All Grades ¹ (%)	Grades 3–4 ¹ (%)
Chemistry				
Increased AST	86	16	90	16
Increased Alkaline Phosphatase	70	4	76	4.6
Increased ALT	62	8	70	4.6
Decreased Albumin	60	1.5	54	0.7
Decreased Sodium	54	13	49	9
Increased Glucose	48	9	43	4.6
Decreased Calcium	30	0.3	35	1.3
Decreased Phosphorus	26	4.7	58	16
Increased Potassium	23	1.9	16	2
Hypomagnesemia	22	0	22	0
Hematology				
Decreased Platelet	68	7	63	4.6
Decreased Lymphocytes	62	13	58	11
Decreased Hemoglobin	58	3.1	62	3.9
Increased Bilirubin	57	8	59	14
Decreased Leukocyte	32	3.4	29	1.3
Decreased Neutrophil	23	2.3	16	1.1

Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous atezolizumab plus bevacizumab (222-323) and sorafenib (90-153)

¹ Graded per NCI CTCAE v4.0

Adverse Reactions in Adult Patients with Melanoma

The safety of TECENTRIQ HYBREZA for its approved melanoma indication [see *Indications and Usage (1.4)*] has been established in adequate and well-controlled studies of intravenous atezolizumab for melanoma (IMspire150 study).

Metastatic Melanoma

IMspire150

The safety of intravenous atezolizumab, administered with cobimetinib and vemurafenib, was evaluated in IMspire150, a double-blind, randomized (1:1), placebo-controlled study conducted in patients with previously untreated BRAF V600 mutation-positive metastatic or unresectable melanoma [see *Clinical Studies (14.4)*]. Patients received intravenous atezolizumab with cobimetinib and vemurafenib (n = 230) or placebo with cobimetinib and vemurafenib (n = 281).

Among the 230 patients who received intravenous atezolizumab administered with cobimetinib and vemurafenib, the median duration of exposure to intravenous atezolizumab was 9.2 months (range: 0–30 months), to cobimetinib was 10.0 months (range: 1–31 months) and to vemurafenib was 9.8 months (range: 1–31 months).

Fatal adverse reactions occurred in 3% of patients in the intravenous atezolizumab plus cobimetinib and vemurafenib arm. Adverse reactions leading to death were hepatic failure, fulminant hepatitis, sepsis, septic shock, pneumonia, and cardiac arrest.

Serious adverse reactions occurred in 45% of patients in the intravenous atezolizumab plus cobimetinib and vemurafenib arm. The most frequent ($\geq 2\%$) serious adverse reactions were hepatotoxicity (7%), pyrexia (6%), pneumonia (4.3%), malignant neoplasms (2.2%), and acute kidney injury (2.2%).

Adverse reactions leading to discontinuation of intravenous atezolizumab occurred in 21% of patients in the intravenous atezolizumab plus cobimetinib and vemurafenib arm. The most frequent ($\geq 2\%$) adverse reactions leading to intravenous atezolizumab discontinuation were increased ALT (2.2%) and pneumonitis (2.6%).

Adverse reactions leading to interruption of intravenous atezolizumab occurred in 68% of patients in the intravenous atezolizumab plus cobimetinib and vemurafenib arm. The most frequent ($\geq 2\%$) adverse reactions leading to intravenous atezolizumab interruption were pyrexia (14%), increased ALT (13%), hyperthyroidism (10%), increased AST (10%), increased lipase (9%), increased amylase (7%), pneumonitis (5%), increased CPK (4.3%), diarrhea (3.5%), pneumonia (3.5%), asthenia (3%), rash (3%), influenza (3%), arthralgia (2.6%), fatigue (2.2%), dyspnea (2.2%), cough (2.2%), peripheral edema (2.2%), uveitis (2.2%), bronchitis (2.2%), hypothyroidism (2.2%), and respiratory tract infection (2.2%).

Tables 21 and 22 summarize the incidence of adverse reactions and laboratory abnormalities in IMspire150.

Table 21: Adverse Reactions Occurring in $\geq 10\%$ of Patients on the Intravenous Atezolizumab plus Cobimetinib and Vemurafenib Arm or the Placebo plus Cobimetinib and Vemurafenib Arm and at a Higher Incidence (Between Arm Difference of $\geq 5\%$ All Grades or $\geq 2\%$ Grades 3-4 Intravenous Atezolizumab in IMspire150)

Adverse Reaction	Intravenous Atezolizumab in combination with Cobimetinib and Vemurafenib (n=230)		Placebo with Cobimetinib and Vemurafenib (n=281)	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
Skin and Subcutaneous Tissue Disorders				
Rash ¹	75	27	72	23
Pruritus	26	< 1	17	< 1
Photosensitivity reaction	21	< 1	25	3.2
General Disorders and Administration Site Conditions				
Fatigue ²	51	3	45	1.8
Pyrexia ³	49	1.7	35	2.1
Edema ⁴	26	< 1	21	0
Gastrointestinal Disorders				
Hepatotoxicity ⁵	50	21	36	13
Nausea	30	< 1	32	2.5
Stomatitis ⁶	23	1.3	15	< 1
Musculoskeletal and Connective Tissue Disorders				
Musculoskeletal pain ⁷	62	4.3	48	3.2
Endocrine Disorders				
Hypothyroidism ⁸	22	0	10	0
Hyperthyroidism	18	< 1	8	0
Injury, Poisoning and Procedural Complications				
Infusion-related reaction ⁹	10	2.6	8	< 1
Respiratory, Thoracic and Mediastinal Disorders				
Pneumonitis ¹⁰	12	1.3	6	< 1
Vascular Disorders				
Hypertension ¹¹	17	10	18	7

¹ Includes rash, rash maculo-papular, dermatitis acneiform, rash macular, rash erythematous, eczema, skin exfoliation, rash papular, rash pustular, palmar-plantar erythrodysesthesia syndrome, dermatitis, dermatitis contact, erythema multiforme, rash pruritic, drug eruption, nodular rash, dermatitis allergic, exfoliative rash, dermatitis exfoliative generalized and rash morbilliform

² Includes fatigue, asthenia and malaise

³ Includes pyrexia and hyperpyrexia

⁴ Includes edema peripheral, lymphoedema, edema, face edema, eyelid edema, periorbital edema, lip edema and generalized edema

- ⁵ Includes alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, transaminases increased, hepatitis, hepatic enzyme increased, hepatotoxicity, hypertransaminasemia, bilirubin conjugated increased, hepatocellular injury, hyperbilirubinemia, liver function test increased, hepatic failure, hepatitis fulminant and liver function test abnormal
- ⁶ Includes stomatitis, mucosal inflammation, aphthous ulcer, mouth ulceration, cheilitis and glossitis
- ⁷ Includes arthralgia, myalgia, pain in extremity, back pain, musculoskeletal pain, arthritis, neck pain, musculoskeletal chest pain, musculoskeletal stiffness, bone pain, spinal pain, immune-mediated arthritis, joint stiffness and non-cardiac chest pain
- ⁸ Includes hypothyroidism and blood thyroid stimulating hormone increased
- ⁹ Includes infusion related reaction and hypersensitivity
- ¹⁰ Includes pneumonitis and interstitial lung disease
- ¹¹ Includes hypertension, blood pressure increased, hypertensive crisis

Clinically important adverse reactions in < 10% of patients who received intravenous atezolizumab plus cobimetinib and vemurafenib were:

Cardiac Disorders: Arrhythmias, ejection fraction decreased, electrocardiogram QT prolonged

Eye Disorders: Uveitis

Gastrointestinal disorders: Pancreatitis

Infections and infestations: Pneumonia, urinary tract infection

Metabolism and nutrition disorders: Hyperglycemia

Nervous system Disorders: Dizziness, dysgeusia, syncope

Respiratory, thoracic and mediastinal disorders: Dyspnea, oropharyngeal pain

Skin and Subcutaneous Tissue Disorders: Vitiligo

Table 22: Laboratory Abnormalities Worsening from Baseline Occurring in $\geq 20\%$ of Patients Receiving Intravenous Atezolizumab Plus Cobimetinib and Vemurafenib Arm or the Placebo Plus Cobimetinib and Vemurafenib Arm and at a Higher Incidence (Between Arm Difference of $\geq 5\%$ All Grades or $\geq 2\%$ Grades 3–4) in IMspire150

Laboratory Abnormality	Intravenous Atezolizumab in combination with Cobimetinib and Vemurafenib (n=230)		Placebo with Cobimetinib and Vemurafenib (n=281)	
	All Grades (%)	Grades 3–4 (%)	All Grades (%)	Grades 3–4 (%)
Hematology				
Decreased Lymphocytes	80	24	72	17
Decreased Hemoglobin	77	2.6	72	2.2
Decreased Platelet	34	1.3	24	0.4
Decreased Neutrophils	26	2.2	19	1.5
Chemistry				
Increased Creatine Kinase	88	22	81	18
Increased AST	80	13	68	6
Increased ALT	79	18	62	12
Increased Triacylglycerol Lipase	75	46	62	35
Increased Alkaline Phosphatase	73	6	63	2.9
Decreased Phosphorus	67	22	64	14
Increased Amylase	51	13	45	13
Increased Blood Urea Nitrogen	47	NA ¹	37	NA ¹
Decreased Albumin	43	0.9	34	1.5
Increased Bilirubin	42	3.1	33	0.7
Decreased Calcium	41	1.3	28	0
Decreased Sodium	40	5	34	7
Decreased Thyroid-Stimulating Hormone	38	NA ¹	23	NA ¹
Increased Thyroid-Stimulating Hormone ²	37	NA ¹	33	NA ¹
Decreased Potassium	36	5	22	4.3
Increased Triiodothyronine	33	NA ¹	18	NA ¹
Increased Free Thyroxine	32	NA ¹	21	NA ¹
Decreased Total Triiodothyronine	32	NA ¹	8	NA ¹
Increased Potassium	29	1.3	19	1.4
Decreased Triiodothyronine	27	NA ¹	21	NA ¹
Increased Sodium	20	0	13	0.4

Graded per NCI CTCAE v4.0.

Each test incidence is based on the number of patients who had both baseline and at least one on-study laboratory measurement available: intravenous atezolizumab plus cobimetinib and vemurafenib (28-277), placebo plus cobimetinib and vemurafenib arm (25-230).

¹ NA = Not applicable. NCI CTCAE v4.0 does not include these laboratories

² Increased Thyroid Stimulating Hormone has a difference < 5% (All Grades) between arms and is included for clinical completeness

Adverse Reactions in Adults with Alveolar Soft Part Sarcoma

The safety of TECENTRIQ HYBREZA for its approved alveolar soft part sarcoma (ASPS) indication [see *Indications and Usage (1.5)*] has been established in adequate and well-controlled studies of intravenous atezolizumab for ASPS (ML39345 study).

Alveolar Soft Part Sarcoma

ML39345 Study

The safety of intravenous atezolizumab was evaluated in 47 adult and 2 pediatric patients enrolled in Study ML39345 [see *Clinical Studies (14.5)*]. Adult patients received intravenous atezolizumab 1200 mg every 3 weeks and pediatric patients received 15 mg/kg up to a maximum 1200 mg every 3 weeks until disease progression or unacceptable toxicity. The median duration of exposure to intravenous atezolizumab was 8.9 months (1 to 40 months).

Serious adverse reactions occurred in 41% of patients receiving intravenous atezolizumab. The most frequent serious adverse reactions (> 2%) were fatigue, pain in extremity, pulmonary hemorrhage, and pneumonia (4.1% each).

Dosage interruptions of intravenous atezolizumab due to an adverse reaction occurred in 35% of patients. The most common adverse reactions (≥ 3%) leading to dose interruptions were pneumonitis and pain in extremity (4.1% each).

Tables 23 and 24 summarize adverse reactions and laboratory abnormalities in Study ML39345.

Table 23: Adverse Reactions Occurring in ≥ 15% of Patients with ASPS Receiving Intravenous Atezolizumab in ML39345

Adverse Reaction	Intravenous Atezolizumab N = 49	
	All Grades (%)	Grades 3–4 (%)
General disorders and administration site conditions		
Fatigue	55	2
Pyrexia	25	2
Influenza like illness	18	0
Gastrointestinal disorders		
Nausea	43	0
Vomiting	37	0
Constipation	33	0
Diarrhea	27	2
Abdominal pain ¹	25	0

Metabolism and nutrition disorders		
Decreased appetite	22	2
Respiratory, Thoracic and Mediastinal		
Cough ²	45	0
Dyspnea	33	0
Rhinitis allergic	16	0
Musculoskeletal and connective tissue disorders		
Musculoskeletal pain ³	67	8
Skin and subcutaneous tissue disorders		
Rash ⁴	47	2
Nervous system disorders		
Headache	43	4
Dizziness ⁵	29	4
Vascular disorders		
Hypertension	43	6
Hemorrhage ⁶	29	2
Psychiatric disorders		
Insomnia	27	0
Anxiety	25	0
Cardiac Disorders		
Arrhythmia ⁷	22	2
Endocrine disorders		
Hypothyroidism ⁸	25	0
Investigations		
Weight decreased	18	0
Weight increased	16	6

Graded per NCI CTCAE v4.0

¹ Includes abdominal pain and abdominal pain upper

² Includes cough, upper-airway cough syndrome, and productive cough

³ Includes arthralgia, pain in extremity, myalgia, non-cardiac chest pain, neck pain, musculoskeletal chest pain, and back pain

⁴ Includes rash maculo-papular, rash, dermatitis acneiform, eczema, skin exfoliation, and drug eruption

⁵ Includes vertigo and dizziness

⁶ Includes pulmonary hemorrhage, hemoptysis, conjunctival hemorrhage, epistaxis, hematuria, rectal hemorrhage, and laryngeal hemorrhage

⁷ Includes atrial fibrillation, sinus bradycardia, ventricular tachycardia, and sinus tachycardia

⁸ Includes hypothyroidism and blood thyroid stimulating hormone increased

Table 24: Laboratory Abnormalities Worsening from Baseline Occurring in $\geq 20\%$ of Patients with ASPS Receiving Intravenous Atezolizumab in ML39345

Laboratory Abnormality ¹	Intravenous Atezolizumab ²	
	All Grades (%)	Grades 3–4 (%)
Hematology		
Decreased Hemoglobin	63	0
Decreased Platelets	27	0
Increased Platelets	29	0
Chemistry		
Increased Alkaline Phosphatase	29	0
Decreased Amylase	40	0
Increased Amylase	20	20
Decreased Bilirubin	49	0
Decreased Calcium	47	0
Increased Calcium	25	14
Decreased Glucose	33	0
Increased Glucose	78	0
Decreased Glucose (fasting)	25	0
Decreased Magnesium	21	0
Increased Magnesium	26	26
Increased AST	39	2
Increased ALT	33	2
Decreased Sodium	43	0
Increased Lipase	25	25

¹ Laboratory tests which do not have NCI CTCAE grading criteria are also included for All Grade assessments, which were performed by comparing to respective lab normal ranges

² The denominators used to calculate the rate varied from 4–49 for all tests of interest based on the number of patients with a baseline value and at least one on-study laboratory measurement available

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of intravenous atezolizumab. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

- Cardiac: pericarditis, pericardial effusion, cardiac tamponade
- Musculoskeletal and Connective Tissue: tenosynovitis

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Based on its mechanism of action [see *Clinical Pharmacology (12.1)*], TECENTRIQ HYBREZA can cause fetal harm when administered to a pregnant woman. There are no available data on the use of TECENTRIQ HYBREZA in pregnant women.

Animal studies have demonstrated that inhibition of the PD-L1/PD-1 pathway can lead to increased risk of immune-related rejection of the developing fetus resulting in fetal death (see *Data*). Advise females of reproductive potential of the potential risk to a fetus [see *Warnings and Precautions (5.4)*].

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Data

Animal Data:

TECENTRIQ HYBREZA for subcutaneous injection contains atezolizumab and hyaluronidase [see *Description (11)*].

Atezolizumab: Animal reproduction studies have not been conducted with atezolizumab to evaluate its effect on reproduction and fetal development. A literature-based assessment of the effects on reproduction demonstrated that a central function of the PD-L1/PD-1 pathway is to preserve pregnancy by maintaining maternal immune tolerance to a fetus. Blockage of PD-L1 signaling has been shown in murine models of pregnancy to disrupt tolerance to a fetus and to result in an increase in fetal loss; therefore, potential risks of administering atezolizumab during pregnancy include increased rates of abortion or stillbirth. As reported in the literature, there were no malformations related to the blockade of PD-L1/PD-1 signaling in the offspring of these animals; however, immune-mediated disorders occurred in PD-1 and PD-L1 knockout mice. Based on its mechanism of action, fetal exposure to atezolizumab may increase the risk of developing immune-mediated disorders or altering the normal immune response.

Hyaluronidase: In an embryo-fetal study, mice were dosed daily by subcutaneous injection during the period of organogenesis with hyaluronidase (recombinant human) at dose levels up to 2,200,000 U/kg, which is > 2,400 times higher than the human dose. The study found no evidence of teratogenicity. Reduced fetal weight and increased numbers of fetal resorptions were observed, with no effects found at a daily dose of 360,000 U/kg, which is > 400 times higher than the human dose.

In a peri-and post-natal reproduction study, mice have been dosed daily by subcutaneous injection, with hyaluronidase (recombinant human) from implantation through lactation and weaning at dose levels up to 1,100,000 U/kg, which is > 1,200 times higher than the human dose. The study found no adverse effects on sexual maturation, learning and memory or fertility of the offspring.

8.2 Lactation

Risk Summary

There is no information regarding the presence of atezolizumab or hyaluronidase in human milk or its effects on the breastfed child, or on milk production. Maternal IgG is known to be present in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed child to TECENTRIQ HYBREZA are unknown. Because of the potential for

serious adverse reactions in breastfed children from TECENTRIQ HYBREZA, advise women not to breastfeed during treatment with TECENTRIQ HYBREZA and for 5 months after the last dose.

8.3 Females and Males of Reproductive Potential

Based on its mechanism of action, TECENTRIQ HYBREZA can cause fetal harm when administered to a pregnant woman [see *Use in Specific Populations (8.1)*].

Pregnancy Testing

Verify pregnancy status in females of reproductive potential prior to initiating TECENTRIQ HYBREZA [see *Warnings and Precautions (5.4)* and *Use in Specific Populations (8.1)*].

Contraception

Females: Advise females of reproductive potential to use effective contraception during treatment with TECENTRIQ HYBREZA and for 5 months following the last dose.

Infertility

Females: Based on animal studies, TECENTRIQ HYBREZA may impair fertility in females of reproductive potential while receiving TECENTRIQ HYBREZA treatment [see *Nonclinical Toxicology (13.1)*].

8.4 Pediatric Use

Alveolar Soft Part Sarcoma

The safety and effectiveness of TECENTRIQ HYBREZA as monotherapy for the treatment of pediatric patients (12 years of age and older who weigh 40 kg or greater) with unresectable or metastatic alveolar soft part sarcoma (ASPS) has been established. Use of TECENTRIQ HYBREZA for this pediatric indication is supported by evidence from adequate and well controlled studies of intravenous atezolizumab in adults, and additional pharmacokinetic and safety data for intravenous atezolizumab in pediatric patients 12 years and older [see *Adverse Reactions (6.1)* and *Clinical Studies (14)*]. Atezolizumab exposures following subcutaneous administration of TECENTRIQ HYBREZA (containing 1,875 mg of atezolizumab) every 3 weeks in pediatric patients 12 years of age and older who weigh 40 kg or greater are predicted to be within the range of those observed in adults at the same dosage.

The safety and effectiveness of TECENTRIQ HYBREZA have not been established in pediatric patients <12 years of age with unresectable or metastatic ASPS.

Solid Tumors and Lymphomas

The safety and effectiveness of TECENTRIQ HYBREZA in pediatric patients have not been established for other approved indications.

8.5 Geriatric Use

TECENTRIQ HYBREZA as a Single-Agent

Of 247 adult patients treated with TECENTRIQ HYBREZA as monotherapy in IMscin001, 45% were 65 years and over and 10% were 75 years and over. No overall differences in safety or effectiveness of TECENTRIQ HYBREZA have been observed between patients aged 65 years or older and younger adult patients.

The safety of TECENTRIQ HYBREZA as monotherapy or in combination with other antineoplastic drugs for its approved indications [see *Indications and Usage (1.1, 1.2, 1.3, 1.4, 1.5)*] has been established in adequate and well-controlled studies of intravenous atezolizumab as

a single agent and in combination with other antineoplastic drugs. Below is a description of geriatric use information from the intravenous atezolizumab studies.

Intravenous Atezolizumab as a Single-Agent

Of 2,616 adult patients with metastatic NSCLC and other tumor types treated with monotherapy intravenous atezolizumab in clinical studies, 49% were 65 years and over and 15% were 75 years and over. No overall differences in safety or effectiveness were observed between intravenous atezolizumab-treated patients aged 65 years or older and younger patients.

Intravenous Atezolizumab in Combination with Other Antineoplastic Drugs

Of 2,421 adult patients with NSCLC and EC-SCLC treated with intravenous atezolizumab in combination with other antineoplastic drugs in clinical studies, 48% were 65 years and over and 10% were 75 years and over.

No overall differences in safety or effectiveness were observed between intravenous atezolizumab-treated patients aged 65 years or older and younger adult patients.

Intravenous Atezolizumab in Combination with Lurbinectedin

Of 242 adult patients with ES-SCLC treated with intravenous atezolizumab in combination with lurbinectedin in IMforte, 124 (51%) patients were 65 years of age and older, while 29 (12%) patients were 75 years of age and older. No overall differences in effectiveness were observed between older and younger patients. There was a higher incidence of Grade 3 or 4 adverse reactions (45% vs 31%) and treatment discontinuation (11% vs 0.8%) in patients \geq 65 years of age compared to younger patients, respectively.

11 DESCRIPTION

TECENTRIQ HYBREZA is a fixed-combination drug product containing atezolizumab and hyaluronidase (human recombinant).

- Atezolizumab is a programmed cell death ligand 1 (PD-L1) blocking antibody. Atezolizumab is an Fc-engineered, humanized, non-glycosylated IgG1 kappa immunoglobulin that has a calculated molecular mass of 145 kDa.
- Hyaluronidase (human recombinant) is an endoglycosidase used to increase the dispersion and absorption of co-administered drugs administered subcutaneously. It is a glycosylated single-chain protein produced by mammalian (Chinese Hamster Ovary) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20). Hyaluronidase (human recombinant) has a molecular weight of approximately 61 kDa.

TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs) injection for subcutaneous use is a sterile, preservative-free, clear and slightly opalescent, and colorless to slightly yellow solution in single-dose vials. Each 15 mL single-dose vial contains 1,875 mg of atezolizumab, 30,000 units of hyaluronidase, histidine (46.5 mg), methionine (22.4 mg), polysorbate 20 (9 mg), sucrose (1,232 mg), and water for injection, adjusted to pH 5.8 with acetic acid.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

PD-L1 may be expressed on tumor cells and/or tumor infiltrating immune cells and can contribute to the inhibition of the anti-tumor immune response in the tumor microenvironment. Binding of PD-L1 to the PD-1 and B7.1 receptors found on T-cells and antigen presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation and cytokine production.

Atezolizumab is a monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors. This releases the PD-L1/PD-1 mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity. In syngeneic mouse tumor models, blocking PD-L1 activity resulted in decreased tumor growth.

In mouse models of cancer, dual inhibition of the PD-1/PD-L1 and MAPK pathways suppresses tumor growth and improves tumor immunogenicity through increased antigen presentation and T-cell infiltration and activation compared to targeted therapy alone.

Hyaluronan is a polysaccharide found in the extracellular matrix of the subcutaneous tissue. It is depolymerized by the naturally occurring enzyme hyaluronidase. Unlike the stable structural components of the interstitial matrix, hyaluronan has a half-life of approximately 0.5 days.

Hyaluronidase increases permeability of the subcutaneous tissue by depolymerizing hyaluronan. In the doses administered, hyaluronidase in TECENTRIQ HYBREZA acts transiently and locally. The effects of hyaluronidase are reversible and permeability of the subcutaneous tissue is restored within 24 to 48 hours.

12.2 Pharmacodynamics

The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of atezolizumab and hyaluronidase have not been fully characterized.

12.3 Pharmacokinetics

When comparing atezolizumab exposure following subcutaneous TECENTRIQ HYBREZA to that of intravenous atezolizumab in Study IMscin001 [see *Clinical Studies (14.1)*], the geometric mean ratio (GMR) (90% CI) for Cycle 1 C_{trough} was 1.05 (0.88, 1.24) and $AUC_{0-21\text{days}}$ was 0.87 (0.83, 0.92); the steady state C_{trough} was 1.15 (1.05, 1.26) and AUC was 1.01 (0.94, 1.08).

Steady-state was achieved 6 to 9 weeks. The systemic accumulation ratio following administration of the approved recommended dosage of TECENTRIQ HYBREZA was 2.2.

Absorption

The mean absolute bioavailability (CV%) of atezolizumab was 72% (83%) and the median time (range) to reach maximum atezolizumab concentration (T_{max}) was 4.5 (2.2, 9) days.

Distribution

The volume of distribution of atezolizumab at steady state was 6.9 L.

Elimination

The atezolizumab clearance (CV%) was 0.2 L/day (29%) and the terminal half-life was 27 days. Atezolizumab clearance decreased over time, with a mean maximal reduction (CV%) from baseline value of 17% (41%); this decrease in clearance is not considered clinically significant.

Specific Populations

No clinically significant differences in the pharmacokinetics of atezolizumab were observed based on age, body weight, sex, albumin levels, tumor burden, region, race, mild or moderate renal impairment (estimated glomerular filtration rate 30 to 89 mL/minute/1.73 m²), mild hepatic impairment (bilirubin \leq ULN and AST $>$ ULN or bilirubin $>$ 1 to 1.5 \times ULN and any AST), moderate hepatic impairment (bilirubin $>$ 1.5 to 3 \times ULN and any AST), level of PD-L1 expression, and performance status.

Pediatric patients

Atezolizumab exposure following subcutaneous administration of atezolizumab 1875 mg and 30,000 units hyaluronidase every 3 weeks in pediatric patients aged 12 years and older who weigh 40 kg or greater is predicted to be within range of those observed in adult patients at the same dosage.

12.6 Immunogenicity

The observed incidence of anti-drug antibodies (ADA) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADA in the studies described below with the incidence of ADA in other studies, including those of TECENTRIQ HYBREZA or of other atezolizumab products or hyaluronidase products.

During the first year of treatment in the Study IMscin001 [see *Clinical Studies (14.1)*], the incidence of ADA was 20% (43/221) and the incidence of neutralizing antibodies (NAb) in ADA-positive patients was 54% (21/39) for TECENTRIQ HYBREZA. The corresponding incidence of ADA was 14% (15/108) and NAb was 60% (9/15) for intravenous atezolizumab.

In Study IMscin001, atezolizumab clearance increased by 29% in patients who received TECENTRIQ HYBREZA and who tested positive for ADA, compared to patients who tested negative for ADA; this change in clearance is not expected to be clinically significant. Because of limited immunogenicity data the effect of ADA on the effectiveness of TECENTRIQ HYBREZA is unknown. There was no identified clinically significant effect of anti-atezolizumab antibodies on the safety of TECENTRIQ HYBREZA during the first 6 months of treatment.

In Study IMscin001, the incidence of anti-rHuPH20 antibodies was 5.4% (12/224) and the incidence of NAb was 0% (0/12). Because of the low occurrence of anti-rHuPH20 antibodies, the effect of these antibodies on the pharmacokinetics, pharmacodynamics and/or safety of hyaluronidase in TECENTRIQ HYBREZA is unknown.

Immunogenicity with Other Clinical Trials with Intravenous Atezolizumab:

During the first year of treatment with intravenous atezolizumab across clinical studies of patients with NSCLC, SCLC, HCC, and melanoma 13% to 36% of patients developed anti-atezolizumab antibodies. Across clinical studies, the NAb incidence in ADA-positive patients was 24% to 83%.

In OAK and IMbrave150, exploratory analyses showed that the subset of patients who were ADA-positive appeared to have less efficacy (effect on overall survival) as compared to patients who tested negative for ADA [see *Clinical Studies (14.1, 14.3)*]. In study IMpower150 and IMforte, the impact of ADA on efficacy did not appear to be clinically significant [see *Clinical Studies (14.1)*]. In the remaining studies, there is insufficient information to characterize the effect of ADA on efficacy.

Median atezolizumab clearance in patients who tested positive for ADA was 19% (range of 18% to 49%) higher as compared to atezolizumab clearance in patients who tested negative for ADA; this change in clearance is not expected to be clinically significant. The presence of ADA did not have a clinically significant effect on the incidence or severity of adverse reactions. The effect of NAb on atezolizumab exposure and safety did not appear to be clinically significant. The effect of NAb on key efficacy endpoints is uncertain due to small sample sizes.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No studies have been performed to test the potential of atezolizumab for carcinogenicity or genotoxicity.

Animal fertility studies have not been conducted with atezolizumab; however, an assessment of the male and female reproductive organs was included in a 26-week, repeat-dose toxicity study in cynomolgus monkeys. Weekly administration of atezolizumab to female monkeys at the highest dose tested caused an irregular menstrual cycle pattern and a lack of newly formed corpora lutea in the ovaries. This effect occurred at an estimated AUC approximately 6 times the AUC in patients receiving the recommended intravenous atezolizumab dose and was reversible. There was no effect on the male monkey reproductive organs.

Hyaluronidases are found in most tissues of the body. Long-term animal studies have not been performed to assess the carcinogenic or mutagenic potential of hyaluronidase. In addition, when up to 220,000 units/kg of subcutaneous hyaluronidase (recombinant human) was administered to cynomolgus monkeys for 39 weeks, which is > 223 times higher than the human recommended dose for hyaluronidase, no evidence of toxicity to the male or female reproductive system was found through periodic monitoring of in-life parameters (e.g., semen analyses, hormone levels, menstrual cycles, and also from gross pathology, histopathology and organ weight data).

13.2 Animal Toxicology and/or Pharmacology

In animal models, inhibition of PD-L1/PD-1 signaling increased the severity of some infections and enhanced inflammatory responses. *Mycobacterium tuberculosis*-infected PD-1 knockout mice exhibit markedly decreased survival compared with wild-type controls, which correlated with increased bacterial proliferation and inflammatory responses in these animals. PD-L1 and PD-1 knockout mice and mice receiving PD-L1 blocking antibody have also shown decreased survival following infection with lymphocytic choriomeningitis virus.

14 CLINICAL STUDIES

14.1 Non-Small Cell Lung Cancer

NSCLC - TECENTRIQ HYBREZA

IMscin001 (NCT03735121) was an open-label, multi-center, international, randomized study conducted in adult patients with locally advanced or metastatic NSCLC who were not exposed to cancer immunotherapy and who have disease progression following platinum-based chemotherapy. Patients were excluded if they had a history of autoimmune disease; active or corticosteroid-dependent brain metastases; received a live, attenuated vaccine within 4 weeks prior to randomization; or received systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive drugs within 2 weeks prior to randomization. A total of 371 patients were randomized 2:1 to receive either TECENTRIQ HYBREZA (containing 1,875 mg of atezolizumab and 30,000 units of hyaluronidase) administered subcutaneously in the thigh every 3 weeks (n = 247) or intravenous atezolizumab 1,200 mg every 3 weeks (n = 124) until disease progression or unacceptable toxicity.

The primary outcome measure was atezolizumab exposure (C_{trough} and $AUC_{0-21\text{days}}$) of subcutaneous TECENTRIQ HYBREZA as compared to intravenous atezolizumab [see *Clinical Pharmacology* (12.3)]. Additional descriptive efficacy outcome measures were overall response rate (ORR), progression-free survival (PFS) and overall survival (OS).

The median age was 64 years (range: 27 to 85); 69% were male; 67% were White, 22% were Asian, and 0.8% were Black or African American; 74% were non-Hispanic or Latino; 26% had

an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 74% had an ECOG PS of 1; and 70% of patients were current or previous smokers. Sixty-five percent of patients had non-squamous histology, 5% had known EGFR mutations, 1.6% had known ALK rearrangements, 36% had known PD-L1 positive tumors, 16% had asymptomatic CNS metastases at baseline. Eighty percent of patients had received only one prior therapeutic regimen for NSCLC.

At the primary analysis, the confirmed ORR was 9% (95% CI: 5, 13) in the subcutaneous TECENTRIQ HYBREZA arm and 8% (95% CI: 4, 14) in the intravenous atezolizumab arm. After further follow up, no notable differences in PFS and OS were observed between patients who received subcutaneous TECENTRIQ HYBREZA and patients who received intravenous atezolizumab.

NSCLC Trials - Intravenous Atezolizumab

The effectiveness of TECENTRIQ HYBREZA has been established for:

- adjuvant treatment (following tumor resection and platinum-based chemotherapy) in adult patients with stage II to IIIA NSCLC whose tumors have PD-L1 expression on $\geq 1\%$ of tumor cells (IMpower010 study).
- first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained $\geq 50\%$ of tumor cells [TC $\geq 50\%$] or PD-L1 stained tumor-infiltrating immune cells [IC] covering $\geq 10\%$ of the tumor area [IC $\geq 10\%$]), with no EGFR or ALK genomic tumor aberrations (IMpower110 study).
- first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations (IMpower150 study).
- first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations (IMpower130 study).
- first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression, with no EGFR or ALK genomic tumor aberrations (OAK study).

Use of TECENTRIQ HYBREZA for these NSCLC indications is supported by evidence from the adequate and well-controlled studies conducted with intravenous atezolizumab in these NSCLC populations and pharmacokinetics data that demonstrated comparable exposures to atezolizumab between TECENTRIQ HYBREZA and intravenous atezolizumab in the IMscin001 trial [see *Adverse Reactions (6.1)*, *Clinical Pharmacology (12.3)*, and *Clinical Studies (14.1)*]. Below is a description of the efficacy results of these adequate and well-controlled studies of intravenous atezolizumab in these NSCLC populations.

Adjuvant Treatment of Early-stage NSCLC

IMpower010

The efficacy of intravenous atezolizumab was evaluated in IMpower010 (NCT02486718), a multi-center, randomized, open-label trial for the adjuvant treatment of patients with NSCLC who had complete tumor resection and were eligible to receive cisplatin-based adjuvant chemotherapy. Eligible patients were required to have Stage IB (tumors ≥ 4 cm) – Stage IIIA NSCLC per the Union for International Cancer Control/American Joint Committee on Cancer staging system, 7th edition. Patients were excluded if they had a history of autoimmune disease; a history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis; administration of a live, attenuated vaccine within 28 days prior to randomization; administration of systemic immunostimulatory

agents within 4 weeks or systemic immunosuppressive medications within 2 weeks prior to randomization.

A total of 1005 patients who had complete tumor resection and received cisplatin-based adjuvant chemotherapy were randomized (1:1) to receive intravenous atezolizumab 1200 mg intravenous infusion every 3 weeks for 16 cycles, unless disease recurrence or unacceptable toxicity occurred, or best supportive care (BSC). Randomization was stratified by sex, stage of disease, histology, and PD-L1 expression.

Tumor assessments were conducted at baseline of the randomization phase and every 4 months for the first year following Cycle 1, Day 1 and then every 6 months until year five, then annually thereafter.

The median age was 62 years (range: 26 to 84), and 67% of patients were male. The majority of patients were White (73%) and Asian (24%). Most patients were current or previous smokers (78%) and baseline Eastern Cooperative Oncology Group (ECOG) performance status in patients was 0 (55%) or 1 (44%). Overall, 12% of patients had Stage IB, 47% had Stage II and 41% had Stage IIIA disease. PD-L1 expression, defined as the percentage of tumor cells expressing PD-L1 as measured by the VENTANA PD-L1 (SP263) assay, was $\geq 1\%$ in 53% of patients, $< 1\%$ in 44% and unknown in 2.6%.

The primary efficacy outcome measure was disease-free survival (DFS) as assessed by the investigator. The primary efficacy analysis population (n = 476) was patients with Stage II – IIIA NSCLC with PD-L1 expression on $\geq 1\%$ of tumor cells (PD-L1 $\geq 1\%$ TC). DFS was defined as the time from the date of randomization to the date of occurrence of any of the following: first documented recurrence of disease, new primary NSCLC, or death due to any cause, whichever occurred first. A key secondary efficacy outcome measure was overall survival (OS) in the intent-to-treat population.

At the time of the interim DFS analysis, the study demonstrated a statistically significant improvement in DFS in the PD-L1 $\geq 1\%$ TC, Stage II – IIIA patient population.

Efficacy results are presented in Table 25 and Figure 1.

Table 25: Efficacy Results from IMpower010 in Patients with Stage II - IIIA NSCLC with PD-L1 expression $\geq 1\%$ TC

	Arm A: Intravenous Atezolizumab N = 248	Arm B: Best Supportive Care N = 228
Disease-Free Survival		
Number of events (%)	88 (35)	105 (46)
Median, months	NR	35.3
(95% CI)	(36.1, NE)	(29.0, NE)
Hazard ratio ¹ (95% CI)	0.66 (0.50, 0.88)	
p-value	0.004	


CI = Confidence interval, NE = Not estimable, NR = Not reached

¹ Stratified by stage, sex, and histology

In a pre-specified secondary subgroup analysis of patients with PD-L1 TC $\geq 50\%$ Stage II – IIIA NSCLC (n = 229), the median DFS was not reached (95% CI: 42.3 months, NE) for patients in the intravenous atezolizumab arm and was 35.7 months (95% CI: 29.7, NE) for patients in the

best supportive care arm, with a HR of 0.43 (95% CI: 0.27, 0.68). In an exploratory subgroup analysis of patients with PD-L1 TC 1-49% Stage II – IIIA NSCLC (n = 247), the median DFS was 32.8 months (95% CI:29.4, NE) for patients in the intravenous atezolizumab arm and 31.4 months (95% CI: 24.0, NE) for patients in the best supportive care arm, with a HR of 0.87 (95% CI: 0.60, 1.26).

Figure 1: Kaplan-Meier Plot of Disease-Free Survival in IMpower010 in Patients with Stage II – IIIA NSCLC with PD-L1 expression $\geq 1\%$ TC



At the time of the DFS interim analysis, 19% of patients in the PD-L1 $\geq 1\%$ TC Stage II – IIIA patient population had died. An exploratory analysis of OS in this population resulted in a stratified HR of 0.77 (95% CI: 0.51, 1.17).

Metastatic Chemotherapy-Naïve NSCLC

IMpower110

The efficacy of intravenous atezolizumab was evaluated in IMpower110 (NCT02409342), a multicenter, international, randomized, open-label trial in patients with stage IV NSCLC whose tumors express PD-L1 (PD-L1 stained $\geq 1\%$ of tumor cells [TC $\geq 1\%$] or PD-L1 stained tumor-infiltrating immune cells [IC] covering $\geq 1\%$ of the tumor area [IC $\geq 1\%$]), who had received no prior chemotherapy for metastatic disease. PD-L1 tumor status was determined based on immunohistochemistry (IHC) testing using the VENTANA PD-L1 (SP142) Assay. The evaluation of efficacy is based on the subgroup of patients with high PD-L1 expression (TC $\geq 50\%$ or IC $\geq 10\%$), excluding those with EGFR or ALK genomic tumor aberrations. The trial excluded patients with a history of autoimmune disease, administration of a live attenuated vaccine within 28 days prior to randomization, active or untreated CNS metastases, administration of systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medications within 2 weeks prior to randomization.

Randomization was stratified by sex, ECOG performance status, histology (non-squamous vs. squamous) and PD-L1 expression (TC \geq 1% and any IC vs. TC < 1% and IC \geq 1%). Patients were randomized (1:1) to receive one of the following treatment arms:

- Arm A: Intravenous atezolizumab 1200 mg every 3 weeks until disease progression or unacceptable toxicity
- Arm B: Platinum-based chemotherapy

Arm B platinum-based chemotherapy regimens for non-squamous NSCLC consisted of cisplatin (75 mg/m²) and pemetrexed (500 mg/m²) OR carboplatin (AUC 6 mg/mL/min) and pemetrexed (500 mg/m²) on Day 1 of each 21-day cycle for a maximum of 4 or 6 cycles followed by pemetrexed (500 mg/m²) until disease progression or unacceptable toxicity.

Arm B platinum-based chemotherapy regimens for squamous NSCLC consisted of cisplatin (75 mg/m²) on Day 1 with gemcitabine (1250 mg/m²) on Days 1 and 8 of each 21-day cycle OR carboplatin (AUC 5 mg/mL/min) on Day 1 with gemcitabine (1000 mg/m²) on Days 1 and 8 of each 21-day cycle for a maximum of 4 or 6 cycles followed by best supportive care until disease progression or unacceptable toxicity.

Administration of intravenous atezolizumab was permitted beyond RECIST-defined disease progression. Tumor assessments were conducted every 6 weeks for the first 48 weeks following Cycle 1, Day 1 and then every 9 weeks thereafter. Tumor specimens were evaluated prospectively using the VENTANA PD-L1 (SP142) Assay at a central laboratory and the results were used to define subgroups for pre-specified analyses.

The major efficacy outcome measure was overall survival (OS) sequentially tested in the following subgroups of patients, excluding those with EGFR or ALK genomic tumor aberrations: TC \geq 50% or IC \geq 10%; TC \geq 5% or IC \geq 5%; and TC \geq 1% or IC \geq 1%.

Among the 205 chemotherapy-naïve patients with stage IV NSCLC with high PD-L1 expression (TC \geq 50% or IC \geq 10%) excluding those with EGFR or ALK genomic tumor aberrations, the median age was 65.0 years (range: 33 to 87), and 70% of patients were male. The majority of patients were White (82%) and Asian (17%). Baseline ECOG performance status was 0 (36%) or 1 (64%); 88% were current or previous smokers; and 76% of patients had non-squamous disease while 24% of patients had squamous disease.

The trial demonstrated a statistically significant improvement in OS for patients with high PD-L1 expression (TC \geq 50% or IC \geq 10%) at the time of the OS interim analysis. There was no statistically significant difference in OS for the other two PD-L1 subgroups (TC \geq 5% or IC \geq 5%; and TC \geq 1% or IC \geq 1%) at the interim or final analyses. Efficacy results for patients with NSCLC with high PD-L1 expression are presented in Table 26 and Figure 2.

Table 26: Efficacy Results from IMpower110 in Patients with NSCLC with High PD-L1 Expression (TC \geq 50% or IC \geq 10%) and without EGFR or ALK Genomic Tumor Aberrations

	Arm A: Intravenous Atezolizumab N = 107	Arm B: Platinum-Based Chemotherapy N = 98
Overall Survival¹		
Deaths (%)	44 (41%)	57 (58%)
Median, months	20.2	13.1
(95% CI)	(16.5, NE)	(7.4, 16.5)

	Arm A: Intravenous Atezolizumab N = 107	Arm B: Platinum-Based Chemotherapy N = 98
Hazard ratio ² (95% CI)	0.59 (0.40, 0.89)	
p-value ³	0.0106 ⁴	

¹ Based on OS interim analysis. The median survival follow-up time in patients was 15.7 months


² Stratified by sex and ECOG performance status

³ Based on the stratified log-rank test compared to Arm A

⁴ Compared to the allocated alpha of 0.0413 (two-sided) for this interim analysis

CI = confidence interval; NE = not estimable

Figure 2: Kaplan-Meier Plot of Overall Survival in IMpower110 in Patients with NSCLC with High PD-L1 Expression (TC ≥ 50% or IC ≥ 10%) and without EGFR or ALK Genomic Tumor Aberrations



Investigator-assessed PFS showed an HR of 0.63 (95% CI: 0.45, 0.88), with median PFS of 8.1 months (95% CI: 6.8, 11.0) in the intravenous atezolizumab arm and 5 months (95% CI: 4.2, 5.7) in the platinum-based chemotherapy arm. The investigator-assessed confirmed ORR was 38% (95% CI: 29%, 48%) in the intravenous atezolizumab arm and 29% (95% CI: 20%, 39%) in the platinum-based chemotherapy arm.

First-Line Metastatic Non-squamous NSCLC

IMpower150

The efficacy of intravenous atezolizumab with bevacizumab, paclitaxel, and carboplatin was evaluated in IMpower150 (NCT02366143), a multicenter, international, randomized (1:1:1), open-label trial in patients with metastatic non-squamous NSCLC. Patients with stage IV non-squamous NSCLC who had received no prior chemotherapy for metastatic disease but could

have received prior EGFR or ALK kinase inhibitor if appropriate, regardless of PD-L1 or T-effector gene (tGE) status and ECOG performance status 0 or 1 were eligible. The trial excluded patients with a history of autoimmune disease, administration of a live attenuated vaccine within 28 days prior to randomization, active or untreated CNS metastases, administration of systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medications within 2 weeks prior to randomization, or clear tumor infiltration into the thoracic great vessels or clear cavitation of pulmonary lesions as seen on imaging. Randomization was stratified by sex, presence of liver metastases, and PD-L1 expression status on tumor cells (TC) and tumor-infiltrating immune cells (IC) as follows: TC3 and any IC vs. TC0/1/2 and IC2/3 vs. TC0/1/2 and IC0/1. Patients were randomized to one of the following three treatment arms:

- Arm A: intravenous atezolizumab 1200 mg, paclitaxel 175 mg/m² or 200 mg/m² and carboplatin AUC 6 mg/mL/min on Day 1 of each 21-day cycle for a maximum of 4 or 6 cycles
- Arm B: intravenous atezolizumab 1200 mg, bevacizumab 15 mg/kg, paclitaxel 175 mg/m² or 200 mg/m², and carboplatin AUC 6 mg/mL/min on Day 1 of each 21-day cycle for a maximum of 4 or 6 cycles
- Arm C: bevacizumab 15 mg/kg, paclitaxel 175 mg/m² or 200 mg/m², and carboplatin AUC 6 mg/mL/min on Day 1 of each 21-day cycle for a maximum of 4 or 6 cycles

Patients who had not experienced disease progression following the completion or cessation of platinum-based chemotherapy, received:

- Arm A: intravenous atezolizumab 1200 mg intravenously on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity
- Arm B: intravenous atezolizumab 1200 mg and bevacizumab 15 mg/kg intravenously on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity
- Arm C: bevacizumab 15 mg/kg intravenously on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity

Tumor assessments were conducted every 6 weeks for the first 48 weeks following Cycle 1, Day 1 and then every 9 weeks thereafter. Tumor specimens were evaluated prior to randomization for PD-L1 tumor expression using the VENTANA PD-L1 (SP142) assay at a central laboratory. Tumor tissue was collected at baseline for expression of tGE signature and evaluation was performed using a clinical trial assay in a central laboratory prior to the analysis of efficacy outcome measures.

Major efficacy outcome measures for comparison of Arms B and C were progression free survival (PFS) by RECIST v1.1 in the tGE-WT (patients with high expression of T-effector gene signature [tGE], excluding those with EGFR- and ALK-positive NSCLC [WT]) and in the ITT-WT subpopulations and overall survival (OS) in the ITT-WT subpopulation. Additional efficacy outcome measures for comparison of Arms B and C or Arms A and C were PFS and OS in the ITT population, OS in the tGE-WT subpopulation, and ORR/DoR in the tGE-WT and ITT-WT subpopulations.

A total of 1202 patients were enrolled across the three arms of whom 1045 were in the ITT-WT subpopulation and 447 were in the tGE-WT subpopulation. The demographic information is limited to the 800 patients enrolled in Arms B and C where efficacy has been demonstrated. The median age was 63 years (range: 31 to 90), and 60% of patients were male. The majority of patients were White (82%), 13% of patients were Asian, 10% were Hispanic, and 2% of patients were Black. Clinical sites in Asia (enrolling 13% of the study population) received paclitaxel at a

dose of 175 mg/m² while the remaining 87% received paclitaxel at a dose of 200 mg/m². Approximately 14% of patients had liver metastases at baseline, and most patients were current or previous smokers (80%). Baseline ECOG performance status was 0 (43%) or 1 (57%). PD-L1 was TC3 and any IC in 12%, TC0/1/2 and IC2/3 in 13%, and TC0/1/2 and IC0/1 in 75%. The demographics for the 696 patients in the ITT-WT subpopulation were similar to the ITT population except for the absence of patients with EGFR- or ALK-positive NSCLC.

The trial demonstrated a statistically significant improvement in PFS between Arms B and C in both the tGE-WT and ITT-WT subpopulations, but did not demonstrate a significant difference for either subpopulation between Arms A and C based on the final PFS analyses. In the interim analysis of OS, a statistically significant improvement was observed for Arm B compared to Arm C, but not for Arm A compared to Arm C. Efficacy results for the ITT-WT subpopulation are presented in Table 27 and Figure 3.

Table 27: Efficacy Results in ITT-WT Population in IMpower150

	Arm C: Bevacizumab, Paclitaxel and Carboplatin	Arm B: Intravenous Atezolizumab with Bevacizumab, Paclitaxel, and Carboplatin	Arm A: Intravenous Atezolizumab with Paclitaxel, and Carboplatin
	N = 337	N = 359	N = 349
Overall Survival¹			
Deaths (%)	197 (59%)	179 (50%)	179 (51%)
Median, months	14.7	19.2	19.4
(95% CI)	(13.3, 16.9)	(17.0, 23.8)	(15.7, 21.3)
Hazard ratio ² (95% CI)	---	0.78 (0.64, 0.96)	0.84 (0.72, 1.08)
p-value ³	---	0.016 ⁴	0.204 ⁵
Progression-Free Survival⁶			
Number of events (%)	247 (73%)	247 (69%)	245 (70%)
Median, months	7.0	8.5	6.7
(95% CI)	(6.3, 7.9)	(7.3, 9.7)	(5.6, 6.9)
Hazard ratio ² (95% CI)	---	0.71 (0.59, 0.85)	0.94 (0.79, 1.13)
p-value ³	---	0.0002 ⁷	0.5219
Objective Response Rate⁶			
Number of responders (%)	142 (42%)	196 (55%)	150 (43%)
(95% CI)	(37, 48)	(49, 60)	(38, 48)
Complete Response	3 (1%)	14 (4%)	9 (3%)
Partial Response	139 (41%)	182 (51%)	141 (40%)
Duration of Response⁶	n = 142	n = 196	n = 150
Median, months	6.5	10.8	9.5
(95% CI)	(5.6, 7.6)	(8.4, 13.9)	(7.0, 13.0)

¹ Based on OS interim analysis

² Stratified by sex, presence of liver metastases, and PD-L1 expression status on TC and IC

³ Based on the stratified log-rank test compared to Arm C

⁴ Compared to the allocated $\alpha=0.0174$ (two sided) for this interim analysis


⁵ Compared to the allocated $\alpha=0.0128$ (two sided) for this interim analysis

⁶ As determined by independent review facility (IRF) per RECIST v1.1 (Response Evaluation Criteria in Solid Tumors v1.1)

⁷ Compared to the allocated $\alpha=0.006$ (two sided) for the final PFS analysis

CI = confidence interval

Figure 3: Kaplan-Meier Curves for Overall Survival in ITT-WT Population in IMpower150



Exploratory analyses showed that the subset of patients in the four drug regimen arm who were ADA positive by week 4 (30%) appeared to have similar efficacy (effect on overall survival) as compared to patients who tested negative for treatment-emergent ADA by week 4 (70%) [see, *Clinical Pharmacology* (12.6)]. In an exploratory analysis, propensity score matching was conducted to compare ADA positive patients in the intravenous atezolizumab, bevacizumab, paclitaxel, and carboplatin arm with a matched population in the bevacizumab, paclitaxel, and carboplatin arm. Similarly, ADA negative patients in the intravenous atezolizumab, bevacizumab, paclitaxel, and carboplatin arm were compared with a matched population in the bevacizumab, paclitaxel, and carboplatin arm. Propensity score matching factors were: baseline sum of longest tumor size (BSLD), baseline ECOG, baseline albumin, baseline LDH, sex, tobacco history, metastatic site, TC level, and IC level. The hazard ratio comparing the ADA-positive subgroup with its matched control was 0.69 (95% CI: 0.44, 1.07). The hazard ratio comparing the ADA-negative subgroup with its matched control was 0.64 (95% CI: 0.46, 0.90).

IMpower130

The efficacy of intravenous atezolizumab with paclitaxel protein-bound and carboplatin was evaluated in IMpower130 (NCT02367781), a multicenter, randomized (2:1), open-label trial in patients with stage IV non-squamous NSCLC. Patients with Stage IV non-squamous NSCLC who had received no prior chemotherapy for metastatic disease, but could have received prior EGFR or ALK kinase inhibitor, if appropriate, were eligible. The trial excluded patients with history of autoimmune disease, administration of live attenuated vaccine within 28 days prior to

randomization, administration of immunostimulatory agents within 4 weeks or systemic immunosuppressive medications within 2 weeks prior to randomization, and active or untreated CNS metastases. Randomization was stratified by sex, presence of liver metastases, and PD-L1 tumor expression according to the VENTANA PD-L1 (SP142) assay as follows: TC3 and any IC vs. TC0/1/2 and IC2/3 vs. TC0/1/2 and IC0/1. Patients were randomized to one of the following treatment regimens:

- Intravenous atezolizumab 1200 mg on Day 1, paclitaxel protein-bound 100 mg/m² on Days 1, 8, and 15, and carboplatin AUC 6 mg/mL/min on Day 1 of each 21-day cycle for a maximum of 4 or 6 cycles followed by intravenous atezolizumab 1200 mg once every 3 weeks until disease progression or unacceptable toxicity, or
- Paclitaxel protein-bound 100 mg/m² on Days 1, 8 and 15 and carboplatin AUC 6 mg/mL/min on Day 1 of each 21-day cycle for a maximum of 4 or 6 cycles followed by best supportive care or pemetrexed.

Tumor assessments were conducted every 6 weeks for the first 48 weeks, then every 9 weeks thereafter. Major efficacy outcome measures were PFS by RECIST v1.1 and OS in the subpopulation of patients evaluated for and documented to have no EGFR or ALK genomic tumor aberrations (ITT-WT).

A total of 724 patients were enrolled; of these, 681 (94%) were in the ITT-WT population. The median age was 64 years (range: 18 to 86) and 59% were male. The majority of patients were White (90%), 2% of patients were Asian, 5% were Hispanic, and 4% were Black. Baseline ECOG performance status was 0 (41%) or 1 (58%). Most patients were current or previous smokers (90%). PD-L1 tumor expression was TC0/1/2 and IC0/1 in 73%; TC3 and any IC in 14%; and TC0/1/2 and IC2/3 in 13%.

Efficacy results for the ITT-WT population are presented in Table 28 and Figure 4.

Table 28: Efficacy Results from IMpower130

	Intravenous Atezolizumab with Paclitaxel Protein-Bound and Carboplatin	Paclitaxel Protein-Bound and Carboplatin
Overall Survival¹	n = 453	n = 228
Deaths (%)	228 (50%)	131 (57%)
Median, months	18.6	13.9
(95% CI)	(15.7, 21.1)	(12.0, 18.7)
Hazard ratio ² (95% CI)	0.80 (0.64, 0.99)	
p-value ³	0.0384 ⁴	
Progression-Free Survival⁶	n = 453	n = 228
Number of events (%)	330 (73%)	177 (78%)
Median, months	7.2	6.5
(95% CI)	(6.7, 8.3)	(5.6, 7.4)
Hazard ratio ² (95% CI)	0.75 (0.63, 0.91)	
p-value ³	0.0024 ⁵	
Overall Response Rate^{6,7}	n = 453	n = 228
Number of responders (%)	207 (46%)	74 (32%)
(95% CI)	(41, 50)	(26, 39)
Complete Response	22 (5%)	2 (1%)
Partial Response	185 (41%)	72 (32%)
Duration of Response^{6,7}	n = 207	n = 74
Median, months	10.8	7.8
(95% CI)	(9.0, 14.4)	(6.8, 10.9)

¹ Based on OS interim analysis

² Stratified by sex and PD-L1 tumor expression on tumor cells (TC) and tumor infiltrating cells (IC)

³ Based on the stratified log-rank test

⁴ Compared to the allocated $\alpha=0.0428$ (two sided) for this interim analysis


⁵ Compared to the allocated $\alpha=0.006$ (two sided) for the final PFS analysis

⁶ As determined by independent review facility (IRF) per RECIST v1.1 (Response Evaluation Criteria in Solid Tumors v1.1)

⁷ Confirmed response

CI = confidence interval

Figure 4: Kaplan-Meier Curves for Overall Survival in IMpower130



Previously Treated Metastatic NSCLC

OAK

The efficacy of intravenous atezolizumab was evaluated in a multicenter, international, randomized (1:1), open-label study (OAK; NCT02008227) conducted in patients with locally advanced or metastatic NSCLC whose disease progressed during or following a platinum-containing regimen. Patients with a history of autoimmune disease, symptomatic or corticosteroid-dependent brain metastases, or requiring systemic immunosuppression within 2 weeks prior to enrollment were ineligible. Randomization was stratified by PD-L1 expression tumor-infiltrating immune cells (IC), the number of prior chemotherapy regimens (1 vs. 2), and histology (squamous vs. non-squamous).

Patients were randomized to receive intravenous atezolizumab 1200 mg intravenously every 3 weeks until unacceptable toxicity, radiographic progression, or clinical progression or docetaxel 75 mg/m² intravenously every 3 weeks until unacceptable toxicity or disease progression. Tumor assessments were conducted every 6 weeks for the first 36 weeks and every 9 weeks thereafter. Major efficacy outcome measure was overall survival (OS) in the first 850 randomized patients and OS in the subgroup of patients with PD-L1-expressing tumors (defined as $\geq 1\%$ PD-L1 expression on tumor cells [TC] or immune cells [IC]). Additional efficacy outcome measures were OS in all randomized patients (n = 1225), OS in subgroups based on PD-L1 expression, overall response rate (ORR), and progression free survival as assessed by the investigator per RECIST v.1.1.

Among the first 850 randomized patients, the median age was 64 years (33 to 85 years) and 47% were ≥ 65 years old; 61% were male; 70% were White and 21% were Asian; 15% were current smokers and 67% were former smokers; and 37% had baseline ECOG PS of 0 and 63% had a baseline ECOG PS of 1. Nearly all (94%) had metastatic disease, 74% had non-squamous

histology, 75% had received only one prior platinum-based chemotherapy regimen, and 55% of patients had PD-L1-expressing tumors.

Efficacy results are presented in Table 29 and Figure 5

Table 29: Efficacy Results in OAK

	Intravenous Atezolizumab	Docetaxel
Overall Survival in first 850 patients		
Number of patients	N = 425	N = 425
Deaths (%)	271 (64%)	298 (70%)
Median, months	13.8	9.6
(95% CI)	(11.8, 15.7)	(8.6, 11.2)
Hazard ratio ¹ (95% CI)	0.74 (0.63, 0.87)	
p-value ²	0.0004 ³	
Progression-Free Survival		
Number of Patients	N = 425	N = 425
Events (%)	380 (89%)	375 (88%)
Progression (%)	332 (78%)	290 (68%)
Deaths (%)	48 (11%)	85 (20%)
Median, months	2.8	4.0
(95% CI)	(2.6, 3.0)	(3.3, 4.2)
Hazard ratio ¹ (95% CI)	0.95 (0.82, 1.10)	
Overall Response Rate⁴		
Number of Patients	N = 425	N = 425
ORR, n (%)	58 (14%)	57 (13%)
(95% CI)	(11%, 17%)	(10%, 17%)
Complete Response	6 (1%)	1 (0.2%)
Partial Response	52 (12%)	56 (13%)
Duration of Response³		
	N = 58	N = 57
Median, months	16.3	6.2
(95% CI)	(10.0, NE)	(4.9, 7.6)
Overall Survival in all 1225 patients		
Number of patients	N = 613	N = 612
Deaths (%)	384 (63%)	409 (67%)
Median, months	13.3	9.8
(95% CI)	(11.3, 14.9)	(8.9, 11.3)
Hazard ratio ¹ (95% CI)	0.79 (0.69, 0.91)	
p-value ²	0.0013 ⁵	

¹ Stratified by PD-L1 expression in tumor infiltrating immune cells, the number of prior chemotherapy regimens, and histology


² Based on the stratified log-rank test

³ Compared to the pre-specified allocated α of 0.03 for this analysis

⁴ Per RECIST v1.1 (Response Evaluation Criteria in Solid Tumors v1.1)

⁵ Compared to the allocated α of 0.0177 for this interim analysis based on 86% information using O'Brien-Fleming boundary
 CI = confidence interval; NE = not estimable

Figure 5: Kaplan-Meier Curves of Overall Survival in the First 850 Patients Randomized in OAK



Tumor specimens were evaluated prospectively using the VENTANA PD-L1 (SP142) Assay at a central laboratory and the results were used to define the PD-L1 expression subgroups for pre-specified analyses. Of the 850 patients, 16% were classified as having high PD-L1 expression, defined as having PD-L1 expression on $\geq 50\%$ of TC or $\geq 10\%$ of IC. In an exploratory efficacy subgroup analysis of OS based on PD-L1 expression, the hazard ratio was 0.41 (95% CI: 0.27, 0.64) in the high PD-L1 expression subgroup and 0.82 (95% CI: 0.68, 0.98) in patients who did not have high PD-L1 expression.

Exploratory analyses showed that the subset of patients who were ADA positive by week 4 (21%) appeared to have less efficacy (effect on overall survival) as compared to patients who tested negative for treatment-emergent ADA by week 4 (79%) [see *Clinical Pharmacology* (12.6)]. ADA positive patients by week 4 appeared to have similar OS compared to docetaxel-treated patients. In an exploratory analysis, propensity score matching was conducted to compare ADA positive patients in the intravenous atezolizumab arm with a matched population in the docetaxel arm and ADA negative patients in the intravenous atezolizumab arm with a matched population in the docetaxel arm. Propensity score matching factors were: baseline sum of longest tumor size (BSLD), baseline ECOG, histology (squamous vs. non-squamous), baseline albumin, baseline LDH, gender, tobacco history, metastases status (advanced or local), metastatic site, TC level, and IC level. The hazard ratio comparing the ADA positive subgroup with its matched control was 0.89 (95% CI: 0.61, 1.3). The hazard ratio comparing the ADA negative subgroup with its matched control was 0.68 (95% CI: 0.55, 0.83).

14.2 Small Cell Lung Cancer

The efficacy of TECENTRIQ HYBREZA in combination with chemotherapy for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) has been established in adequate and well-controlled studies of intravenous atezolizumab. Below is a description of the efficacy results of these adequate and well-controlled studies of intravenous atezolizumab in combination with chemotherapy in ES-SCLC (IMpower133 and IMforte studies).

Small Cell Lung Cancer (SCLC)

IMpower133

The efficacy of intravenous atezolizumab with carboplatin and etoposide was investigated in IMpower133 (NCT02763579), a randomized (1:1), multicenter, double-blind, placebo-controlled trial in 403 patients with ES-SCLC. IMpower133 enrolled patients with ES-SCLC who had received no prior chemotherapy for extensive stage disease and ECOG performance status 0 or 1. The trial excluded patients with active or untreated CNS metastases, history of autoimmune disease, administration of a live, attenuated vaccine within 4 weeks prior to randomization, or administration of systemic immunosuppressive medications within 1 week prior to randomization. Randomization was stratified by sex, ECOG performance status, and presence of brain metastases. Patients were randomized to receive one of the following two treatment arms:

- intravenous atezolizumab 1200 mg and carboplatin AUC 5 mg/mL/min on Day 1 and etoposide 100 mg/m² intravenously on Days 1, 2 and 3 of each 21-day cycle for a maximum of 4 cycles followed by intravenous atezolizumab 1200 mg once every 3 weeks until disease progression or unacceptable toxicity, or
- placebo and carboplatin AUC 5 mg/mL/min on Day 1 and etoposide 100 mg/m² intravenously on Days 1, 2, and 3 of each 21-day cycle for a maximum of 4 cycles followed by placebo once every 3 weeks until disease progression or unacceptable toxicity.

Administration of intravenous atezolizumab was permitted beyond RECIST-defined disease progression. Tumor assessments were conducted every 6 weeks for the first 48 weeks following Cycle 1, Day 1 and then every 9 weeks thereafter. Patients treated beyond disease progression had tumor assessment conducted every 6 weeks until treatment discontinuation.

Major efficacy outcome measures were OS and PFS as assessed by investigator per RECIST v1.1 in the intent-to-treat population. Additional efficacy outcome measures included ORR and DoR as assessed by investigator per RECIST v1.1.

A total of 403 patients were randomized, including 201 to the intravenous atezolizumab arm and 202 to the chemotherapy alone arm. The median age was 64 years (range: 26 to 90) and 65% were male. The majority of patients were White (80%); 17% were Asian, 4% were Hispanic and 1% were Black. Baseline ECOG performance status was 0 (35%) or 1 (65%); 9% of patients had a history of brain metastases, and 97% were current or previous smokers. Efficacy results are presented in Table 30 and Figure 6.

Table 30: Efficacy Results from IMpower133

	Intravenous Atezolizumab with Carboplatin and Etoposide	Placebo with Carboplatin and Etoposide
Overall Survival	N = 201	N = 202
Deaths (%)	104 (52%)	134 (66%)
Median, months	12.3	10.3
(95% CI)	(10.8, 15.9)	(9.3, 11.3)
Hazard ratio ³ (95% CI)	0.70 (0.54, 0.91)	
p-value ^{4,5}	0.0069	
Progression-Free Survival^{1,2}	N = 201	N = 202
Number of events (%)	171 (85%)	189 (94%)
Median, months	5.2	4.3
(95% CI)	(4.4, 5.6)	(4.2, 4.5)
Hazard ratio ³ (95% CI)	0.77 (0.62, 0.96)	
p-value ^{4,6}	0.0170	
Objective Response Rate^{1,2,7}	N = 201	N = 202
Number of responders (%)	121 (60%)	130 (64%)
(95% CI)	(53, 67)	(57, 71)
Complete Response (%)	5 (2%)	2 (1%)
Partial Response (%)	116 (58%)	128 (63%)
Duration of Response^{1,2,7}	N = 121	N = 130
Median, months	4.2	3.9
(95% CI)	(4.1, 4.5)	(3.1, 4.2)

¹ As determined by investigator assessment

² per RECIST v1.1 (Response Evaluation Criteria in Solid Tumors v1.1)

³ Stratified by sex and ECOG performance status

⁴ Based on the stratified log-rank test


⁵ Compared to the allocated α of 0.0193 for this interim analysis based on 78% information using O'Brien-Fleming boundary

⁶ Compared to the allocated α of 0.05 for this analysis

⁷ Confirmed response

CI = confidence interval

Figure 6: Kaplan-Meier Plot of Overall Survival in IMpower133



IMforte

The efficacy of intravenous atezolizumab in combination with lurbinectedin as maintenance treatment was evaluated in IMforte (NCT05091567), a randomized, multicenter, open-label study in patients with ES-SCLC. Patients were eligible if their disease had not progressed after completion of four cycles of intravenous atezolizumab, carboplatin and etoposide (induction treatment) and they had an ECOG performance status of 0 or 1. The trial excluded patients with CNS metastases, history of autoimmune disease, or administration of systemic immunosuppressive medications within 1 week prior to enrollment. Unless contraindicated, primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) was mandated for patients assigned to the intravenous atezolizumab with lurbinectedin arm.

The trial randomized 483 patients who had not experienced disease progression following the completion of four cycles of intravenous atezolizumab with carboplatin and etoposide to one of the following two treatment arms:

- Intravenous atezolizumab 1200 mg IV in combination with lurbinectedin 3.2 mg/m² IV once every 3 weeks until disease progression or unacceptable toxicity, or
- Intravenous atezolizumab 1200 mg IV once every 3 weeks until disease progression or unacceptable toxicity

Randomization was stratified by ECOG performance status prior to randomization (0 vs. 1), lactate dehydrogenase (LDH) (\leq ULN vs. $>$ ULN) prior to randomization, presence of liver metastases prior to initial study enrollment (yes vs. no), and prior receipt of prophylactic cranial irradiation (yes vs. no).

The major efficacy outcome measures were OS and PFS by Independent Review Facility per RECIST v1.1.

A total of 483 patients were randomized, including 242 to the intravenous atezolizumab with lurbinectedin arm and 241 to the intravenous atezolizumab arm. The median age was 66 years (range 35 to 85 years); 63% male; 82% White; 13% Asian; 0.8% were Black or African American; 7% were of Hispanic or Latino ethnicity and 98% were current or previous smokers. Baseline ECOG performance status was 0 (43%) or 1 (57%).

Efficacy results are presented in Table 31 and Figures 7 and 8.

Table 31: Efficacy Results from IMforte

	Intravenous Atezolizumab with Lurbinectedin N=242	Intravenous Atezolizumab N=241
Overall Survival ¹		
Deaths (%)	113 (47%)	136 (56%)
Median, months (95% CI)	13.2 (11.9, 16.4)	10.6 (9.5, 12.2)
Hazard ratio ² (95% CI)	0.73 (0.57, 0.95)	
p-value ^{3, 6}	0.0174	
Progression-Free Survival ^{1, 4, 5}		
Number of events (%)	174 (72%)	202 (84%)
Median, months (95% CI)	5.4 (4.2, 5.8)	2.1 (1.6, 2.7)
Hazard ratio ² (95% CI)	0.54 (0.43, 0.67)	
p-value ^{3, 7}	<0.0001	
¹ Measured from the time of randomization ² Stratified by ECOG performance status, LDH level, presence of liver metastases and prior receipt of prophylactic cranial irradiation ³ Based on the stratified log-rank test ⁴ As determined by an IRF ⁵ per RECIST v1.1 (Response Evaluation Criteria in Solid Tumors v1.1) ⁶ Compared to the allocated alpha of 0.0313 (two-sided) for this interim OS analysis. ⁷ Compared to the allocated alpha of 0.001 (two- sided) for this final PFS analysis. CI=confidence interval		

Figure 7: Kaplan-Meier Plot of IRF-assessed Progression-Free Survival in IMforte





Figure 8: Kaplan-Meier Plot of Overall Survival in IMforte



14.3 Hepatocellular Carcinoma

The efficacy of TECENTRIQ HYBREZA in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not

received prior systemic therapy has been established in adequate and well-controlled studies of intravenous atezolizumab in combination with bevacizumab for HCC. Below is a description of the efficacy results of intravenous atezolizumab in combination with bevacizumab in this adequate and well-controlled HCC trial.

Hepatocellular Carcinoma

IMbrave150

The efficacy of intravenous atezolizumab in combination with bevacizumab was investigated in IMbrave150 (NCT03434379), a multicenter, international, open-label, randomized trial in patients with locally advanced unresectable and/or metastatic hepatocellular carcinoma who have not received prior systemic therapy. Randomization was stratified by geographic region (Asia excluding Japan vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), baseline AFP (< 400 vs. \geq 400 ng/mL), and by ECOG performance status (0 vs. 1).

A total of 501 patients were randomized (2:1) to receive either intravenous atezolizumab as an intravenous infusion of 1200 mg, followed by 15 mg/kg bevacizumab, on the same day every 3 weeks or sorafenib 400 mg given orally twice daily, until disease progression or unacceptable toxicity. Patients could discontinue either intravenous atezolizumab or bevacizumab (e.g., due to adverse events) and continue on monotherapy until disease progression or unacceptable toxicity associated with the monotherapy.

The study enrolled patients who were ECOG performance score 0 or 1 and who had not received prior systemic treatment. Patients were required to be evaluated for the presence of varices within 6 months prior to treatment, and were excluded if they had variceal bleeding within 6 months prior to treatment, untreated or incompletely treated varices with bleeding, or high risk of bleeding. Patients with Child-Pugh B or C cirrhosis, moderate or severe ascites; history of hepatic encephalopathy; a history of autoimmune disease; administration of a live, attenuated vaccine within 4 weeks prior to randomization; administration of systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medications within 2 weeks prior to randomization; or untreated or corticosteroid-dependent brain metastases were excluded. Tumor assessments were performed every 6 weeks for the first 54 weeks and every 9 weeks thereafter.

The demographics and baseline disease characteristics of the study population were balanced between the treatment arms. The median age was 65 years (range: 26 to 88) and 83% of patients were male. The majority of patients were Asian (57%) or White (35%); 40% were from Asia (excluding Japan). Approximately 75% of patients presented with macrovascular invasion and/or extrahepatic spread and 37% had a baseline AFP \geq 400 ng/mL. Baseline ECOG performance status was 0 (62%) or 1 (38%). HCC risk factors were Hepatitis B in 48% of patients, Hepatitis C in 22%, and 31% of patients had non-viral liver disease. The majority of patients had BCLC stage C (82%) disease at baseline, while 16% had stage B, and 3% had stage A.

The major efficacy outcome measures were overall survival (OS) and independent review facility (IRF)-assessed progression free survival (PFS) per RECIST v1.1. Additional efficacy outcome measures were IRF-assessed overall response rate (ORR) per RECIST and mRECIST.

Efficacy results are presented in Table 32 and Figure 9.

Table 32: Efficacy Results from IMbrave150

	Intravenous Atezolizumab in combination with Bevacizumab (N= 336)	Sorafenib (N=165)
Overall Survival		
Number of deaths (%)	96 (29)	65 (39)
Median OS in months (95% CI)	NE (NE, NE)	13.2 (10.4, NE)
Hazard ratio ¹ (95% CI)	0.58 (0.42, 0.79)	
p-value ²	0.0006 ²	
Progression-Free Survival³		
Number of events (%)	197 (59)	109 (66)
Median PFS in months (95% CI)	6.8 (5.8, 8.3)	4.3 (4.0, 5.6)
Hazard ratio ¹ (95% CI)	0.59 (0.47, 0.76)	
p-value	< 0.0001	
Overall Response Rate^{3,5} (ORR), RECIST 1.1		
Number of responders (%)	93 (28)	19 (12)
(95% CI)	(23, 33)	(7,17)
p-value ⁴	< 0.0001	
Complete responses, n (%)	22 (7)	0
Partial responses, n (%)	71 (21)	19 (12)
Duration of Response^{3,5} (DOR) RECIST 1.1		
	(n=93)	(n=19)
Median DOR in months (95% CI)	NE (NE, NE)	6.3 (4.7, NE)
Range (months)	(1.3+, 13.4+)	(1.4+, 9.1+)
Overall Response Rate^{3,5} (ORR), HCC mRECIST		
Number of responders (%)	112 (33)	21 (13)
(95% CI)	(28, 39)	(8, 19)
p-value ⁴	< 0.0001	
Complete responses, n (%)	37 (11)	3 (1.8)
Partial responses, n (%)	75 (22)	18 (11)
Duration of Response^{3,5} (DOR) HCC mRECIST		
	(n=112)	(n=21)
Median DOR in months (95% CI)	NE (NE, NE)	6.3 (4.9, NE)
Range (months)	(1.3+, 13.4+)	(1.4+, 9.1+)

¹ Stratified by geographic region (Asia excluding Japan vs. rest of world), macrovascular invasion and/or extrahepatic spread (presence vs. absence), and baseline AFP (< 400 vs. ≥ 400 ng/mL)

² Based on two-sided stratified log-rank test; as compared to significance level 0.004 (2-sided) based on 161/312=52% information using the OBF method

³ Per independent radiology review

⁴ Based on two-sided Cochran-Mantel-Haenszel test


⁵ Confirmed responses

+ Denotes a censored value

CI = confidence interval; HCC mRECIST = Modified RECIST Assessment for Hepatocellular Carcinoma;

NE = not estimable; RECIST 1.1 = Response Evaluation Criteria in Solid Tumors v1.1

Figure 9: Kaplan-Meier Plot of Overall Survival in IMbrave150



Exploratory analyses showed that the subset of patients (20%) who were ADA-positive by week 6 appeared to have reduced efficacy (effect on OS) as compared to patients (80%) who tested negative for treatment-emergent ADA by week 6 [see *Clinical Pharmacology (12.6)*]. ADA-positive patients by week 6 appeared to have similar overall survival compared to sorafenib-treated patients. In an exploratory analysis, inverse probability weighting was conducted to compare ADA-positive patients and ADA-negative patients in the intravenous atezolizumab and bevacizumab arm to the sorafenib arm. Inverse probability weighting factors were: baseline sum of longest tumor size (BSLD), baseline ECOG, baseline albumin, baseline LDH, sex, age, race, geographic region, weight, neutrophil-to-lymphocyte ratio, AFP (< 400 ng/mL vs \geq 400 ng/mL), number of metastatic sites, MVI and/or EHS present at study entry, etiology (HBV vs. HCV vs. non-viral) and Child-Pugh Score (A5 vs. A6). The OS hazard ratio comparing the ADA-positive subgroup of the intravenous atezolizumab and bevacizumab arm to sorafenib was 0.93 (95% CI: 0.57, 1.53). The OS hazard ratio comparing the ADA-negative subgroup to sorafenib was 0.39 (95% CI: 0.26, 0.60).

14.4 Melanoma

The efficacy of TECENTRIQ HYBREZA in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic

melanoma has been established in adequate and well-controlled studies of intravenous atezolizumab in combination with bevacizumab for BRAF V600 mutation-positive unresectable or metastatic melanoma. Below is a description of the efficacy results of intravenous atezolizumab in combination with cobimetinib and vemurafenib in this adequate and well-controlled melanoma trial.

Metastatic Melanoma

IMspire150

The efficacy of intravenous atezolizumab in combination with cobimetinib and vemurafenib was evaluated in a double-blind, randomized (1:1), placebo-controlled, multicenter trial (IMspire150; NCT02908672) conducted in 514 patients. Randomization was stratified by geographic location (North America vs. Europe vs. Australia, New Zealand, and others) and baseline lactate dehydrogenase (LDH) [less than or equal to upper limit of normal (ULN) vs. greater than ULN].

Eligible patients were required to have previously untreated unresectable or metastatic BRAF V600 mutation-positive melanoma as detected by a locally available test and centrally confirmed with the FoundationOne™ assay. Patients were excluded if they had history of autoimmune disease; administration of a live, attenuated vaccine within 28 days prior to randomization; administration of systemic immunostimulatory agents within 4 weeks or systemic immunosuppressive medications within 2 weeks prior to randomization; and active or untreated CNS metastases.

Intravenous atezolizumab was initiated after patients received a 28-day treatment cycle of cobimetinib 60 mg orally once daily (21 days on/7 days off) and vemurafenib 960 mg orally twice daily Days 1-21 and 720 mg orally twice daily Days 22-28. Patients received intravenous atezolizumab 840 mg intravenous infusion over 60 minutes every 2 weeks in combination with cobimetinib 60 mg orally once daily and vemurafenib 720 mg orally twice daily, or placebo in combination with cobimetinib 60 mg orally once daily and vemurafenib 960 mg orally twice daily. Treatment continued until disease progression or unacceptable toxicity. There was no crossover at the time of disease progression. Tumor assessments were performed every 8 weeks (\pm 1 week) for the first 24 months and every 12 weeks (\pm 1 week) thereafter.

The major efficacy outcome measure was investigator-assessed progression-free survival (PFS) per RECIST v1.1. Additional efficacy outcomes included PFS assessed by an independent central review, investigator-assessed ORR, OS, and DOR.

The median age of the study population was 54 years (range: 22–88), 58% of patients were male, 95% were White, a baseline ECOG performance status of 0 (77%) or 1 (23%), 33% had elevated LDH, 94% had metastatic disease, 60% were Stage IV (M1C), 56% had less than three metastatic sites at baseline, 3% had prior treatment for brain metastases, 30% had liver metastases at baseline, and 14% had received prior adjuvant systemic therapy. Based on central testing, 74% were identified as having a V600E mutation, 11% as having V600K mutation, and 1% as having V600D or V600R mutations.

Efficacy results are summarized in Table 33 and Figure 10. Patients had a median survival follow up time of 18.9 months.

Table 33: Efficacy Results from IMspire150

	Intravenous Atezolizumab + Cobimetinib + Vemurafenib N = 256	Placebo + Cobimetinib + Vemurafenib N = 258
Progression-Free Survival¹		
Number of events (%)	148 (58)	179 (69)
Median, months (95% CI)	15.1 (11.4, 18.4)	10.6 (9.3, 12.7)
Hazard ratio ² (95% CI)	0.78 (0.63, 0.97)	
p-value ³	0.0249	
Overall Response Rate^{1,4}		
Number of responders (%) (95% CI)	170 (66) (60, 72)	168 (65) (59, 71)
Complete responses, n (%)	41 (16)	46 (18)
Partial response, n (%)	129 (50)	122 (47)
Duration of Response^{1,4}	n = 170	n = 168
Median, months (95% CI)	20.4 (15.1, NE)	12.5 (10.7, 16.6)


¹ As determined by investigator assessment with Response Evaluation Criteria in Solid Tumors v1.1.;
CI = confidence interval

² Stratified by baseline LDH

³ Based on the stratified log-rank test

⁴ Confirmed responses

Figure 10: Kaplan-Meier Plot for Progression-Free Survival in IMspire150



At a pre-specified analysis at the time of the primary analysis of PFS, the OS data were not mature. The median OS was 28.8 months with 93 (36%) deaths in the intravenous atezolizumab plus cobimetinib and vemurafenib arm, and 25.1 months with 112 (43%) deaths in the placebo plus cobimetinib and vemurafenib arm. The hazard ratio for OS was 0.85 (95% CI: 0.64, 1.11) and the p-value was 0.2310.

14.5 Alveolar Soft Part Sarcoma

The efficacy of TECENTRIQ HYBREZA as monotherapy for the treatment of adult patients and pediatric patients 12 years of age or older with unresectable or metastatic alveolar soft part sarcoma (ASPS) has been established in adequate and well-controlled studies of intravenous atezolizumab for ASPS. Below is a description of the efficacy results of intravenous atezolizumab in this adequate and well-controlled ASPS trial.

The efficacy of intravenous atezolizumab was evaluated in study ML39345 (NCT03141684), an open-label, single-arm study, in 49 adult and pediatric patients aged 2 years and older with unresectable or metastatic ASPS. Eligible patients were required to have histologically or cytologically confirmed ASPS that was not curable by surgery, and an ECOG performance status of ≤ 2 .

Patients were excluded if they had known primary central nervous system (CNS) malignancy or symptomatic CNS metastases, known clinically significant liver disease, or history of idiopathic pulmonary fibrosis, pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.

Adult patients received 1200 mg intravenously and pediatric patients received 15 mg/kg (up to a maximum of 1200 mg) intravenously once every 21 days until disease progression or unacceptable toxicity.

The major efficacy outcomes were Overall Response Rate (ORR) and Duration of Response (DOR) by Independent Review Committee according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.

A total of 49 patients were enrolled. The median age of patients was 31 years (range: 12–70); 2% of adult patients (n = 47) were ≥ 65 years of age and the pediatric patients (n = 2) were ≥ 12 years of age; 51% of patients were female, 55% White, 29% Black or African American, 10% Asian; 53% had an ECOG performance status of 0 and 45% had an ECOG performance status of 1. All patients had prior surgery for ASPS and 55% received at least one prior line of treatment for ASPS; 55% received radiotherapy and 53% received chemotherapy. Of the patients who reported staging at initial diagnosis, all were Stage IV.

Efficacy results of this study are summarized in Table 34.

Table 34: Efficacy Results from Study ML39345

Endpoint	All Patients (N=49)
Overall Response Rate (95% CI)^a	24% (13, 39)
Complete responses, n	0
Partial responses, n (%)	12 (24)
Duration of Response	
Median, month	NE
(95% CI)	(17.0, NE)
Range	1+, 41+
Durability of response	
≥ 6 months, n (%)	8 (67%)
≥ 12 months, n (%)	5 (42%)

CI: confidence interval; N: number of patients; +: Censored

^a 95% CI based on Clopper-Pearson exact method.

14.6 Patient Experience

The IMscin002 study (NCT03735121) was a randomized, multi-center, open-label cross-over trial conducted in 179 patients with either PD-L1-positive early-stage NSCLC receiving adjuvant treatment or were chemotherapy-naïve with high PD-L1 stage IV NSCLC. Patients were randomized (1:1) to receive 3 cycles of TECENTRIQ HYBREZA followed by 3 cycles of intravenous atezolizumab (Arm A) or 3 cycles of intravenous atezolizumab followed by 3 cycles of TECENTRIQ HYBREZA (Arm B).

Of the 126 eligible patients, 123 (98%) completed the patient preference questionnaire at the beginning of cycle 6 or after at least two consecutive cycles of each treatment method was administered in case of treatment discontinuation prior to cycle 6. Eighty-seven of 123 patients (71%) reported preferring subcutaneous administration of TECENTRIQ HYBREZA over intravenous atezolizumab and the most common reason was that administration required less time in the clinic; 26 out of 123 patients (21%) reported preferring intravenous atezolizumab over TECENTRIQ HYBREZA and the most common reason was that it felt more comfortable during administration; and 10 out of 123 patients (8%) had no preference for the route of administration.

Patients in both arms could continue to receive treatment after the crossover period for up to 16 cycles (patients with early-stage NSCLC) or until disease progression or unacceptable toxicity (patients with stage IV NSCLC). Of the 107 patients who reached the treatment continuation period, 85 (79%) patients (42 from IV/SC and 43 from SC/IV) chose to continue treatment with the SC route of administration.

16 HOW SUPPLIED/STORAGE AND HANDLING

TECENTRIQ HYBREZA (atezolizumab and hyaluronidase-tqjs) injection for subcutaneous use is a sterile, preservative-free, clear to slightly opalescent, and colorless to slightly yellow solution. It is supplied in a carton containing:

1,875 mg and 30,000 units/15 mL (125 mg and 2,000 units/mL) in a single-dose vial (NDC 50242-933-01).

Store vials under refrigeration at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. Do not shake.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

Immune-Mediated Adverse Reactions

Inform patients of the risk of immune-mediated adverse reactions that may require corticosteroid treatment and interruption or discontinuation of TECENTRIQ HYBREZA, including:

- *Pneumonitis*: Advise patients to contact their healthcare provider immediately for any new or worsening cough, chest pain, or shortness of breath [see *Warnings and Precautions (5.1)*].
- *Colitis*: Advise patients to contact their healthcare provider immediately for diarrhea, blood or mucus in stools, or severe abdominal pain [see *Warnings and Precautions (5.1)*].
- *Hepatitis*: Advise patients to contact their healthcare provider immediately for jaundice, severe nausea or vomiting, pain on the right side of abdomen, lethargy, or easy bruising or bleeding [see *Warnings and Precautions (5.1)*].
- *Endocrinopathies*: Advise patients to contact their healthcare provider immediately for signs or symptoms of hypophysitis, hyperthyroidism, hypothyroidism, adrenal insufficiency, or type 1 diabetes mellitus, including diabetic ketoacidosis [see *Warnings and Precautions (5.1)*].
- *Nephritis*: Advise patients to contact their healthcare provider immediately for pelvic pain, frequent urination, or unusual swelling [see *Warnings and Precautions (5.1)*].
- *Dermatologic Adverse Reactions*: Advise patients to contact their healthcare provider immediately for generalized rash, skin eruption, or painful skin and mucous membrane lesions [see *Warnings and Precautions (5.1)*].
- *Other Immune-Mediated Adverse Reactions*: Advise patients to contact their healthcare provider immediately for signs or symptoms of other potential immune-mediated adverse reactions [see *Warnings and Precautions (5.1)*].

Infusion-Related Reactions

Advise patients to contact their healthcare provider immediately for signs or symptoms of infusion-related reactions [see *Warnings and Precautions (5.2)*].

Complications of Allogeneic HSCT after PD-1/PD-L1 Inhibitors

Follow patients closely for evidence of transplant-related complications and intervene promptly. Consider the benefits versus risks of treatment with a PD-1/PD-L1 blocking antibody prior to or after an allogeneic HSCT [see *Warnings and Precautions (5.3)*].

Embryo-Fetal Toxicity

Advise females of reproductive potential that TECENTRIQ HYBREZA can cause harm to a fetus and to inform their healthcare provider of a known or suspected pregnancy [see *Warnings and Precautions (5.4), Use in Specific Populations (8.1, 8.3)*].

Advise females of reproductive potential to use effective contraception during treatment and for 5 months after the last dose of TECENTRIQ HYBREZA [see *Use in Specific Populations (8.3)*].

Lactation

Advise female patients not to breastfeed while taking TECENTRIQ HYBREZA and for 5 months after the last dose [see *Use in Specific Populations (8.2)*].

TECENTRIQ HYBREZA[®] (atezolizumab and hyaluronidase-tqjs)

Manufactured by:

Genentech, Inc.

A Member of the Roche Group

1 DNA Way

South San Francisco, CA 94080-4990

U.S. License No.: 1048

TECENTRIQ HYBREZA is a registered
trademark of Genentech, Inc.

©2025 Genentech, Inc.